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ABSTRACT 
The potential treatment approaches for various disorders associated with central nervous system 
are invasive and do not allow frequent administration. Brain targeting of drugs by intranasal 
route is a safe and noninvasive method of drug delivery which allows frequent administration 
and is certainly more patient compliant than the currently followed invasive methods.  
   In this study, the plausibility of delivering neurotrophins [nerve growth factor (NGF) and 
brain derived neurotrophic factor (BDNF)], neurotrophinogenic agents (ex: carnosic acid) and 
antibiotics (ex: cefotaxime) to brain via nose-brain pathway using chitosan as barrier modulating 
agent was investigated. In vitro permeation studies of fluorescein isothiocyanate dextran 
(FD40k) across bovine olfactory mucosa using different viscosity grades chitosan at different 
concentrations indicated that medium viscosity grade chitosan (0.25% w/v) enhanced the 
permeation of FD40k significantly over other grades and concentration of chitosan. Such similar 
results were observed when medium viscosity grade chitosan (0.25% w/v) was used as barrier 
modulating agent in studies involving nerve growth factor, brain derived neurotrophic factor, 
carnosic acid and cefotaxime.  
   The potential of intranasal formulations of therapeutic agents containing medium 
viscosity grade chitosan (0.25% w/v) was explored by carrying out in vivo studies in male 
Sprague-Dawley rats. 
                       The brain bioavailability of group of rats administered intranasally with NGF and BDNF 
solution containing chitosan was significantly enhanced by ~14 fold and ~13 fold, respectively, 
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compared to group of rats administered with same concentration of NGF and BDNF solution 
without chitosan. Pharmacodynamic studies clearly indicated that the immobility time in case of 
rats subjected to immobilization stress was significantly decreased upon intranasal administration 
of BDNF solution containing chitosan. 
 In studies involving carnosic acid the neurotrophin levels (NGF and BDNF) were 
enhanced significantly upon intranasal administration of carnosic acid with chitosan, which was 
~1.5-2 fold more over the parenteral route. When carnosic acid with chitosan formulations were 
administered in the form of nanoparticles only once in contrary to that of solution which was 
administered daily once for a period of 4 days there was no statistically significant difference in 
the NGF and BDNF levels. However, when the formulations were administered in the form of 
solution only once, the NGF and BDNF levels even after 4 days were not statistically significant 
from the vehicle control group. The results clearly indicated that carnosic acid nanoparticles 
could reduce the frequency of administration and also could maintain prolonged therapeutic 
levels due to higher retention time at the site of delivery. 
 The pharmacokinetic studies of cefotaxime indicated that the drug levels attained in the 
brain following i.v and intranasal administrations were comparable. However, the drug levels in 
the plasma following intranasal administration were almost an order of magnitude less when 
compared to that of i.v administration. These results suggested that intranasal administration of 
cefotaxime along with chitosan is likely to result in less systemic side effects compared to 
parenteral administration. 
 Nose to brain delivery of therapeutic agents along with chitosan as barrier modulating 
agent is a potential approach for treating various disorders associated with central nervous 
system.
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CHAPTER-1 
ITRODUCTIO 
 
1.1.  Anatomy of nose 
The human nasal cavity is divided into two cavities by the nasal septum. Each nasal cavity 
(surface area ~75 cm
2
) has three distinct regions, the vestibular, respiratory and olfactory 
regions. The vestibular region is located at the opening of the nasal passage and is responsible 
for filtering of air borne particles and has no absorption function. The respiratory region covers 
most of the dorsal and ventral nasal cavities and is primarily responsible for drug absorption as it 
has the highest degree of vascularity. The olfactory region plays an important role in 
transportation of drugs to the brain and the cerebrospinal fluid (CSF) and it constitutes ~10 cm
2 
in surface area. The olfactory region is situated just below the cribriform plate of the ethamoid 
bone separating the cranial cavity from the nasal cavity (1, 2).  
 
  
 
 
 
  
 
Figure 1: Schematic illustration of human nose indicating the various cell types in the olfactory 
region. [Hilger PA, Fundamentals of Otolaryngology, A Textbook of Ear, #ose and Throat 
Diseases. 6th ed. Philadelphia, PA, 184, Copyright Elsevier (WB Saunders Co) (1989)]. 
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The olfactory epithelium is a modified form of respiratory epithelium consisting of three types of 
cells, the olfactory receptor cells, sustentacular cells and basal cells. The olfactory receptor cells 
are bipolar neurons and are interspersed among sustentacular cells. A single dendritic process 
extends from the cell body to the free apical surface where it terminates as a small knob like 
swelling from which extends a dozen of extremely long modified non motile cilia. At the basal 
aspect of the neuronal cell body, each receptor gives rise to a single fine non-myelinated axon 
and forms large bundles in the lamina propria. The unbranched axons are ensheathed by glial 
cells and cross into the cranial cavity through small holes in the cribriform plate of the ethmoid 
bone. The bundles of nerve fibers travel along the surface of the olfactory bulb, eventually 
synapsing with mitral cell dendrites and other neuronal targets in the glomeruli of the bulb. The 
sustentacular cells are elongated columnar cells with many long microvilli extending from their 
luminal surface to form an entanglement with the cilia of the receptor cells. These cells provide 
mechanical support to the receptor cells. The basal cells are small, conical cells which are able to 
differentiate into neuronal receptor cells (1-3).  
 
1.2.  Pathways of drug absorption 
Intranasally administered drugs reach the brain and/or CSF by different routes as illustrated in 
figure 2. A significant amount of drug may be rapidly cleared by the mucociliary mechanism. 
Some part of the administered drugs (lipophilic) may directly reach the systemic circulation and 
subsequently is eliminated from the blood stream via normal clearance mechanism. The drugs 
can reach the brain from the blood by crossing the blood brain barrier but can also be eliminated 
from the CSF into the blood (1, 4-6). 
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The drug can also be absorbed from the nasal cavity via the olfactory pathway into the CSF and 
possibly further into the brain parenchyma by navigating along one or more of the following 
pathways (Figure 3).  
a).  Paracellular pathway: The transport of drugs by this route is slow and passive. The drugs 
pass through the tight junctions and the open clefts of the epithelial cells present in the nasal 
mucosa. Low molecular weight and/or hydrophilic drugs are usually transported by this route. 
 b). Transcellular pathway: The drugs are transported across the nasal epithelium by either 
passive diffusion or receptor mediated endocytosis or fluid phase endocytosis. Usually, lipophilic 
or large molecular weight compounds are transported by this route. 
 c).  euronal transport: This kind of transport takes place via intercellular axonal transport. 
The olfactory neuron cells facilitate the drug transport principally to the olfactory bulb. 
 
Figure 2:  Schematic overview of possible in vivo fate of drugs following intranasal administration.  
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1.3.  Barriers for drug delivery 
From the results of various studies conducted in animal models it has been reported that the 
direct uptake of drugs into CSF and/or brain upon intranasal administration is affected by 
physico-chemical factors (chemical form, molecular weight, particle size etc.), formulation 
factors (pH, drug concentration, gel forming carriers, preservatives, dose volume etc.) and 
physiological factors (effect of disposition, mucociliary clearance, enzymatic degradation, 
pathological condition etc) (4, 7). Some of the critical factors which limit the brain uptake of 
intranasally administered drugs are discussed below. 
 
Figure 3: The different pathways of drug absorption from the nasal cavity via olfactory 
pathway into brain parenchyma and/or CSF. 
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a).  Low permeability across the olfactory mucosa for polar drugs and macromolecules 
The poor bioavailability of polar drugs (~10%) and peptides (< 1%) across nasal mucosa is 
attributed to the low membrane permeability (5). Tight junctions, although considered as 
dynamic structures which can open and close to a certain degree, the transport of large molecules 
is limited across them (8, 9). Hence the bioavailability is poor as the large molecules are 
transported across the nasal mucosa by endocytosis. Trans-nasal absorption is greatly improved 
by co-administration of absorption enhancing agents. These include cationic compounds 
(chitosan and its derivatives, poly-L-arginine, poly-L-lysine), bile salts and bile salts derivatives 
(sodium deoxycholate, sodium glycocholate, sodium taurodihydrofusidate), fatty acids and fatty 
acid derivatives (linoleic acid), phospholipids (lysophosphatidylcholine) and surfactants (sodium 
laurylsulfate). These enhancers act by either altering the permeability of the epithelial cell layer 
or act on tight junctions or work as enzymatic degradation inhibitors. In animal studies it has 
been reported that there is a direct correlation between the absorption enhancing effect of 
surfactants/ bile salts and the damage caused to the nasal mucosa. In contrary, it has been 
demonstrated that the cationic compounds such as chitosan causes minimal or no damage to the 
nasal mucosa (10).  
 
 b).  Mucociliary clearance  
This is another important factor, which affects the bioavailability of intranasally administered 
drugs due to the rapid clearance of the formulation from the nasal cavity. As a result of 
mucociliary clearance the contact or retention time of the drug at the absorption site is limited. It 
has been reported that for formulations (liquid/powder) which are not bioadhesive the half life 
for clearance is of the order of 15-30 minutes in the nasal cavity thereby resulting in incomplete 
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drug absorption (7, 11). The only approach to overcome the rapid mucociliary clearance is by 
use of bioadhesive excipients in the formulations or by administering the formulation in the less 
ciliated part of the nasal cavity thus leading to improved absorption. Vyas et al., observed a 
higher transport of drug to rat brain upon intranasal administration of mucoadhesive micro-
emulsions of sumatriptan compared to non-mucoadhesive micro-emulsions (12). Kumar et al., 
also demonstrated that bioadhesive nano-emulsions of risperidone could be rapidly and 
efficiently transported to the rat brain upon intranasal administration (13). 
 
c).  Enzymatic degradation  
The poor bioavailability of intranasally administered peptides and proteins is attributed to the 
enzymatic degradation of the molecule in the lumen of the nasal cavity or during passage 
through the epithelial barrier (14). These regions of the nasal cavity contain exopeptidases such 
as mono and diamino peptidases that can cleave peptides at their N and C terminals and 
endopeptidases such as serine and cysteine which can attack internal peptide bonds (15). In 
addition, the proteolytic enzymes and other mucosa secretases in the mucosal secretions can 
form the enzyme barrier in the nasal cavity which produces a pseudo first pass effect thereby 
decreasing the delivery amounts and therapeutic effects of peptides and proteins. In the human 
nasal cavity the enzyme isoforms of cytochrome P450 such as CYP1A, CYP2A and CYP2E are 
found in addition to carboxylesterases, S-transferases, glutathione etc (4). This enzymatic 
degradation of peptides and proteins can be overcome by using enzyme inhibitors/ by saturation 
of enzymes. Graff et al., demonstrated that co-administration of verapamil and enzyme 
(CYP3A4 and P-gp) substrate resulted in the complete elimination of P-gp mediated transport of 
verapamil and significantly enhanced its brain uptake (16).  
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1.4.  Approaches to enhance nose to brain drug delivery  
In addition to the steps taken to overcome the barriers/limitations (low membrane permeability, 
mucociliary clearance and enzymatic degradation) upon intranasal delivery, other approaches 
which are being investigated to augment the nose to brain delivery are discussed as follows.  
 
a).  Prodrug approach 
The critical physicochemical factors which influence the direct drug uptake from nose to brain 
and/or CSF are molecular weight and lipophilicity. Prodrugs are synthesized with an aim to 
modify the structure of the parent drug with favorable physicochemical and biological properties 
for absorption (7, 17). Kao et al., reported that intranasal administration of several alkyl ester 
water soluble prodrugs of L-dopa to rats resulted in significantly higher levels of L-dopa than 
that of the parent drug in the CSF, which was also significantly higher than that of equivalent i.v 
dose (18). Enhancement of nose to brain drug delivery by this approach is an effective method. 
However, such modification may alter the biological activity of the drugs, for example, synthesis 
of protein prodrugs may result from serious disruption of their spatial structures thus 
significantly reducing their activity (7). 
 
b).  Modification of formulations 
The type of formulation also plays an important role on brain uptake of intranasally administered 
drugs as they determine the residence time and local drug concentration in the olfactory mucosa 
(7). Dalpiaz et al., demonstrated that microparticles of N-cyclopentyladenosine (CPA) 
significantly increased the drug delivery to CSF via intranasal administration in rats, while free 
CPA was not able to reach the CSF from nasal cavity or by i.v infusion (19). Kumar et al., also 
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demonstrated that nano-emuslions of risperidone could be efficiently transported to brain upon 
intranasal administration to rats (13). 
 
c).  Agglutinant-mediated transport 
The saccharide groups, N-acetlyglucosamine and L-fucose which are significantly more 
expressed than other saccharide groups present on the nasal mucosa specifically bind to wheat 
germ agglutinin (WGA) and ulex europaeus agglutinin (UEA I), respectively, convey signals to 
the cells, induce endocytosis and then transit to brain (20). Gao et al., reported that after 
intranasal administration of vasoactive intestinal peptide (VIP)-loaded WGA nanoparticles 
(lectin-bearing PEG-polylactic acid) in rats, the active VIP amounts were ~6 times higher in 
cerebrum than that following an intranasal VIP solution (21-23). 
 
d).  Brain homing peptide-mediated 
The brain homing peptides are identified by recovering the phage libraries from the brain upon 
intranasal administration. The recovered phage libraries are then amplified repeatedly in vitro 
and redelivered intranasally to obtain sufficiently enriched peptides to target brain parenchyma 
or CSF (7). Then the valid homing motifs are identified and may be grafted to surface molecules 
of drugs or preparations like liposomes with specific targeting properties (24). Janda reported 
that the cocaine addiction in animal models was effectively treated by delivering the therapeutic 
protein agent directly into the central nervous system (CNS) from the nasal cavity by phage-
based approach (25). 
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1.5.  In vitro and In vivo models 
The most commonly used in vitro models for routinely carried out transport studies of drugs 
across nasal mucosa are excised mucosal tissue or cell culture monolayers (26, 27). From various 
nasal mucosal studies it has been reported that fully organized mucosal tissue is mechanistically 
more relevant to human nasal mucosa than cell lines. Bovine olfactory mucosa was reported to 
be a good in vitro model for human olfactory mucosa with respect to drug transport and 
metabolic pathways in nasal mucosa (27). 
 The transport of various drugs from nasal cavity to brain and/or CSF has been studied in 
rats, mice, rabbits and monkeys, however, most of the studies have been performed in rats (1).  
 
a). Transport of low molecular weight drugs in animal models 
Many low molecular weight drugs have been shown to be transported directly to the brain and/or 
CSF from the nasal cavity (1, 27). Chow et al, studies the brain uptake of cocaine after intranasal 
and i.v administration in rats and reported that there was similar distribution of cocaine in the 
various regions of the brain. However, the cocaine content in samples collected within 60 
minutes after intranasal administration showed highest concentration in the olfactory bulb than 
the remaining parts of the brain. From the results of these studies it was concluded that the rapid 
effect of cocaine on the CNS was due the presence of direct pathway from the nasal cavity to the 
brain (28). Sakane et al., reported that upon intranasal administration of cephalexin in rats, the 
levels in the CSF were ~100 fold higher than when administered by i.v/intraduodenal routes (29). 
Anand Kumar et al., and David et al., reported that the amount of labeled drugs (oestradiol and 
progesterone) that reached the CSF was higher upon intranasal administration in rhesus monkey 
compared to i.v administration (1, 30).  
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b). Transport of large molecular weight drugs in animal models 
A number of protein and peptide drugs have been successfully delivered to the brain and/or CNS 
by intranasal route in variety of species (1). Vajdy et al., reported that the plasma DNA reached 
the brain within 15 minutes following intranasal administration (31). Liu et al., has investigated 
the nose to brain delivery of insulin like growth factor-I (IGF-I) and reported that intranasal 
delivery of IGF-I protects against focal cerebral ischemic damage (32). It has been reported that 
macromolecules such as interferon-β-1b (MW ~18.5 kDa) and vasoactive intestinal peptide (MW 
~3.3 kDa) rapidly achieved peak brain levels upon intranasal administration compared to that 
administered by i.v route (33). Alcala-Barraza et al., demonstrated that intranasal delivery of 
[
125
I]–radiolabeled neurotrophic factors, brain derived neurotrophic factor (BDNF), ciliary 
neurotrophic factor (CNTF), neurotrophin-4 (NT-4) and erythropoietin resulted in substantial 
concentrations within 25 minutes in brain parenchyma (34).  
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                                                           CHAPTER-2 
      CHITOSA 
 
Chitosan is a polycationic linear polysaccharide chemically derived by deacetylation of chitin 
(1:4- linked 2-acetamide-2-deoxy-β-D-glucopyranose), a naturally occurring polymer present in 
shells of crustaceans such as crabs, lobsters, prawns and shrimp (35). Chitosan is available in 
different molecular masses (low < 50 kDa, medium 50-150 kDa, high > 150 kDa), degrees of 
deacetylation (40 - 98%) and viscosities. It is insoluble at neutral and alkaline pH conditions, 
whereas at acidic pH conditions the amino groups are protonated (pKa 6.3) thereby improving the 
solubility. This polymer has wide application in biomedical and pharmaceutical fields due to its 
biocompatible, biodegradable and non-toxic nature (35-37). Among many polymers, chitosan 
has been found to be substantially safe on nasal epithelium (36).  
  The permeation enhancement property of chitosan when applied to nasal mucosal surface 
is attributed to its ability to translocate the proteins zonula occludens-1 (ZO-1) and occludin from 
plasma membrane to cytoplasm and promoting the partial alteration of cytoskeleton thus opening 
tight junction complexes (38). Chitosan may assist paracellular transport of drugs by transiently 
opening the tight junctions existing between the epithelial cells and suppressing the efflux 
transporters as has been shown in Caco-2 cell culture studies and in animal models (39, 40).
 
Schipper et al., studied the influence of molecular weight and degree and acetylation on drug 
transport across human intestinal epithelial (Caco-2) cells and reported that increased molecular  
12 
 
mass and deacetylation degree, improves the chitosan ability to open tight junctions (39). 
Dodane et al., investigated the effect of chitosan solutions (degree of deacetylation 80%, pH 6-
6.5) on the structure and function of Caco-2 cell monolayers using microscopy techniques 
(confocal and transmission electron microscopy) and reported that chitosan had a transient effect 
on the tight junctions permeability and the cells viability was not affected (38). In addition to 
chitosan, its thiolated and quaternized derivatives have been reported to enhance the permeability 
of the nasal mucosa. Krauland et al., demonstrated that intranasal delivery of insulin thiolated 
chitosan to male Wistar rats resulted in significantly higher bioavailability (41). Hamman et al., 
studied the effect of degree of quaternisation of N-trimethyl chitosan chloride (TMC) on 
absorption enhancement of [14C]-mannitol, in vivo in rats and reported that all TMC polymers 
with different degrees of quaternisation (12-59%) increased the nasal absorption of [14C]-
mannitol significantly (42). Some reports exist on the ability of chitosan and its derivatives to 
improve the bioavailability of macromolecules across the nasal epithelium (10, 43). 
  Chitosan is bioadhesive at physiological pH due to the ionic interactions between the 
positively charged amino groups in chitosan and the negatively charged sialic acid residues in 
mucus (39). There is also evidence that chitosan may improve the bioavailability of 
macromolecules in the brain when injected i.v or parenterally. For instance, chitosan based 
microemulsion significantly increased the brain uptake of i.v injected nobiletin in mice (44). 
When doxorubicin loaded chitosan-poly acrylic acid hollow nanospheres are administered 
parenterally to different organs of mice, a significant amount of drug reached the brain. Confocal 
laser scanning microscopy confirmed that the hollow chitosan-poly acrylic acid nanospheres are 
potential carriers for drugs (45). Extensive toxicological and tolerance studies in animal models 
and humans have shown chitosan to be non-toxic and non-irritant to the nasal mucosa (46). 
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CHAPTER-3 
EUROTROPHIS 
 
3.1.  Importance of neurotrophins 
Neurotrophins comprise a large group of proteins which are synthesized as precursors of 
approximately 270 amino acids (30-35 kDa) (47-49). The physiological actions of neurotrophins 
(NTs) have been attributed to mature proteins which function as soluble, non-covalently linked 
homodimers. NTs are uniquely potent molecules which bind to specific receptors and elicit 
biological responses in the nanomolar to femtomolar range (49). The neurotrophin receptors 
consist of single low-affinity receptor (p75
NTR
), a member of tumor necrosis receptor family and 
a high-affinity tropomyosin related kinase (trk) receptor which is made up of three distinct 
members of trk family (50). Most of these proteins act via retrograde signaling from target 
neurons and some NTs function partially, or exclusively as anterograde molecular signals. They 
promote the neuronal survival, stimulate axonal growth and influence axonal findings to 
establish synaptic contacts during development. In addition neurotrophins also represent a 
potential means of modifying astrocytic activation, neuronal dysfunction and inflammatory 
reactions under pathological conditions (47, 49, 51). Hence, many of the neurotrophins are used 
as therapeutic agents for treating various nervous system disorders and injury states, including 
Alzheimer’s, Parkinson’s, multiple sclerosis, motor neuron diseases, stroke and traumatic 
brain/spinal cord conditions (51). The mammalian neurotrophin family contains six members, 
14 
 
nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
neurotrophin-4/5 (NT-4/5), neurotrophin-6 (NT-6) and neurotrophin-7 (NT-7) (49). 
 
3.2.  Disorders associated with neurotrophin depletion 
It has been reported that neurodegenerative disorders such as Alzheimer's, Parkinson's, motor 
neuron diseases and stroke are caused due to depletion of endogenous levels of NTs during the 
neurodegenerative disorders (47). Alzheimer's disease (AD) is the most common form of 
dementia in elderly patients, characterized by memory loss and confusion. During this disease 
state there is substantial decline in the cholinergic function in the cortex and hippocampus region 
of the brain (52, 53). It has been reported that the degeneration of these cholinergic functions in 
AD patients are caused by reduced neurotrophic support that is lack of production of 
NGF/BDNF in the cerebral cortex and hippocampus region (51). Parkinson’s disease is 
degenerative disorder of the CNS which results in rigidity and tremors of the limbs, postural 
instability and bradykinesia of the limbs and body. The symptoms are the result of loss of 
pigmented cells in the substantia nigra and due to the reduction of the neurotransmitter dopamine 
in the striatum. Peripheral neuropathy includes a range of neurological disorders resulting from 
damage to the peripheral nerves. Amyotrophic lateral sclerosis is the most common form of adult 
motor neuron disease. In this disease state the motor neurons in the spinal cord, brain stem and 
motor cortex progressively die (47-49). 
 
3.3. Current treatment approaches 
Currently practiced invasive methods for treating neurodegenerative disorders include 
intraparenchymal or intracerebroventricular or intrathecal routes of administration of NTs (49). 
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For delivery of NTs locally over short distances in the CNS tissues intraparenchymal route is 
preferred. Intraparenchymal route is also ideal for administration of polymer encapsulated 
neurotrophin implants or genetically engineered cells for the continuous supply of NTs (54). In 
order to deliver NTs to wide areas of the CNS, intracerebroventricular route is preferred as it 
results in distribution of NTs within the ventricular and extraventricular CSF (55). Intrathecal 
administration of NTs may result in high local concentrations in the subarachnoid spaces of CSF 
at the lumbar or cisternal spinal cord levels. This route is not commonly preferred for treating 
CNS diseases as the therapeutic levels are rarely attained in contrast to spinal cord diseases (56, 
57). The demerits of these routes for administration of NTs are they are invasive, may cause 
infection and result in damage of tissue during cannula insertion (49). 
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CHAPTER-4 
       OBJECTIVES 
 
The treatment of neurodegenerative disorders with NTs has been a challenging task as most of 
them are not successful in clinical trials due to the poor efficiency of current drug delivery 
methods (58). It has been reported that upon intraventricular or intrathecal infusion of NTs there 
was distribution of the neurotrophins throughout the subarachnoid space of the brain and spinal 
cord, inducing migration of Schwann cells into the CNS, stimulating nociceptive axons, eliciting 
sympathetic axon sprouting around the cerebral vasculature thereby causing weight loss (49). 
Thus, clinical testing of NTs requires a delivery method that is non-invasive, patient compliant 
and effective in delivering therapeutic amounts of NTs to the brain for the treatment of 
neurodegenerative disorders.  
Intranasal administration is a potential route for drug delivery to the brain that bypasses 
the blood–brain barrier (BBB). This route of administration is relatively more patient compliant 
than injections and also allows more frequent administration due to its noninvasiveness.  
 The objective of our study was to investigate the potential of chitosan in enhancing the 
transport of neurotrophins (NGF and BDNF) and neurotrophinogenic agents (ex: carnosic acid) 
via nose to brain pathway thereby enhancing the brain uptake. The other objective was to study 
the pharmacokinetics of these drugs in the perineural fluid employing brain microdialysis 
technique following intranasal administration.  
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CHAPTER-5 
     ERVE GROWTH FACTOR  
 
Nerve growth factor (NGF) a member of neurotrophin family synthesized primarily in the 
hippocampus and neocortex of the brain plays a significant role in promoting growth, 
differentiation and function of both peripheral ganglion cells and central cholinergic neurons of 
the basal forebrain (59-61). NGF was the first neurotrophins family member and the first nervous 
system growth factor to be identified. NGF was originally isolated from mouse sarcoma based on 
its ability to promote the hypertrophy and fiber outgrowth from sensory neurons. NGF is a 
hydrophilic, dimeric protein of ~30 kDa and is not bioavailable to the brain on systemic 
administration due to the brain barriers (61). Prior studies on nose to brain delivery of NGF have 
used the total amount of NGF in the brain tissue homogenate as a measure of successful delivery 
(59, 62). However, the NGF concentration in brain interstitium (perineural fluid that bathes the 
neuronal cell surfaces) as opposed to total concentration in the brain tissue is more relevant in 
predicting the therapeutic effectiveness, adverse effects, and toxicity of neurotrophins. Therefore, 
the time course of concentration of the NGF in the brain interstitial fluid following intranasal 
delivery of NGF was investigated using microdialysis sampling technique. 
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5.1. Materials and Methods 
5.1.1. Chemicals 
Krebs-Ringer bicarbonate (KRB) buffer (premixed powder), crystal violet, gelatin (300 bloom), 
fluorescein isothiocyanate dextran of molecular weight 40 kDa (FD40K), chitosan of different 
grades, low viscosity (20-200 cP), medium viscosity (200-800 cP) and high viscosity (800-2000 
cP) with varying percentage of deacetylation content were procured from Sigma chemicals 
(St.Louis, MO). NGF, 2.5 S, murine and NGF Emax ImmunoAssay system were purchased from 
Promega Corporation, Madison, WI.  
 
5.1.2. Olfactory mucosa 
The bovine olfactory mucosa was purchased from Pel-Freez Biologicals, Arkansas. Bovine 
olfactory mucosa is a good model for human olfactory mucosa with respect to drug transport and 
metabolic pathways in nasal mucosa (27). The tissue was excised freshly and supplied frozen. 
The tissue was used within 24 h of excision. The tissue was thawed for 30 minutes before 
mounting on the diffusion cell. 
 
5.1.3.  In vitro experimental set up 
A vertical Franz diffusion cell (Logan instruments, Somerset, NJ) was used for permeation 
experiments across the bovine olfactory mucosa. The temperature of the chamber was regulated 
at 37 ± 1
0
C by water circulation. Bovine olfactory mucosa was sandwiched between two 
compartments of the diffusion apparatus, one serving as the donor and other as the receiver 
compartment. The olfactory mucosa side was in contact with the upper donor compartment and 
the ventral side with the receiver compartment. The active diffusion area was 0.64 cm
2
. 
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Silver/Silver chloride (Ag/AgCl) electrode wires of 0.5 mm in diameter (obtained from Alfa 
Aesar, Ward Hill, MA) made in the form of circular ring were placed 2 mm away from the 
olfactory mucosa in both donor and the receiver compartments. The donor and the receiver 
compartments were filled with 100 µL and 5 mL KRB buffer, respectively for electrical 
resistance measurements. The AC electrical resistance of the mucosa was measured by placing a 
load resistor RL (100 kΩ) in series with the mucosa. Voltage drop across the whole circuit (VO) 
and across the mucosa (VE) was measured using an electrical set up consisting of a wave form 
generator and multimeter (Agilent Technologies, Santa Clara, CA). For measuring the resistance, 
a small voltage of 100 mV was applied at 10 Hz and the olfactory mucosa resistance in kΩcm
2
 
was approximated from the following formula.  
 
 
Where, RE is the olfactory mucosa resistance and RL is the load resistor in kΩ. 
 
5.1.4.  Preparation of chitosan and FD40K/ GF solution 
Different grades of chitosan solutions were prepared by dissolving required quantity of chitosan 
in a fraction of 1% glacial acetic acid solution prepared in KRB buffer (pH 5.5). The second 
fraction of the KRB buffer was used to dissolve the FD40K/ NGF. The FD40K/ NGF and 
chitosan solutions were mixed by vortexing. The solutions prepared without incorporation of 
chitosan served as control. 
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5.1.5. In vitro permeation studies 
In order to investigate the effect of different viscosity grades chitosan (low viscosity, medium 
viscosity and high viscosity) on the permeation of FD40K, the donor solution was replaced after 
equilibration for 30 minutes with a solution of 500 µL of FD40K (1mg/mL) with different 
concentrations of chitosan (0.1% or 0.25% or 0.5% w/v). The receiver compartment was filled 
with 5 mL KRB buffer. Samples were collected at the end of 2 h from the receiver compartment 
and the amount of FD40K permeated across bovine olfactory mucosa was determined by 
measuring the fluorescence emission intensity at 520 nm by excitation at 494 nm using Perkin 
Elmer fluorimeter. In control set of experiments chitosan was not incorporated in the donor 
solution. 
In another set of studies the donor compartment was filled with 100 µL of NGF solution 
(100 µg/mL prepared in KRB) with medium viscosity grade chitosan of different concentrations 
(0.1% or 0.25% or 0.5% w/v) and the receiver compartment with 5 mL KRB buffer. Control set 
of experiments were run without incorporation of chitosan in the donor solution. The amount of 
NGF permeated across the bovine olfactory mucosa was determined by assaying the samples 
collected from the receiver compartment at the end of 2 h by Enzyme-linked immunosorbent 
assay (ELISA) using “NGF Emax ImmunoAssay system” (see section 5.1.8).  
 
5.1.6. Calibration of microdialysis probe 
The calibration of microdialysis probes (CMA 12, membrane length - 4 mm, diameter 0.5 mm, 
stainless steel shaft diameter 0.64 mm, shaft length 14 mm and MWCO 100 kDa) was carried out 
by successively immersing the probes in dialysis media containing 50, 75 and 100 µg/mL of 
NGF and continuously perfusing with KRB buffer at a flow rate of 2.0 µL/min using a syringe 
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pump controller (BASi, West Lafayette, IN). Probes were equilibrated for a period of 30 minutes 
and then the samples were collected at regular intervals of 1h for a period of 6 h. The percentage 
recovery was calculated as the ratio of dialysate concentration to its concentration in the dialysis 
medium surrounding the probe. 
 
5.1.7. In vivo brain microdialysis 
In vivo experiments were carried out in male, Sprague dawley rats (250–300 g, Harlan Company, 
Indianapolis, IN, U.S.A.) under ketamine (80 mg/kg) and xylazine (10 mg/kg) anesthesia (i.p 
injection). The experimental procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Mississippi (Protocol # 07–025). The rats were divided 
into 3 groups (n=3 for each). 
Intranasal vehicle control group (0.25% w/v chitosan in KRB buffer); Intranasal NGF 
group (NGF solution prepared in KRB buffer); Intranasal NGF + Chitosan group (NGF solution 
prepared in 0.25% w/v chitosan in KRB buffer).  
The procedure followed for carrying out microdialysis is briefly discussed as follows: 
Step  1) All the instruments used were clean and sterilized. 
Step  2) The rats were anesthetized and the head was shaved.  
Step 3) The animals were laid on their back and the formulations were administered intranasally 
using a using a microsyringe connected with a soft polymer capillary directly into the posterior 
segment of the nose. 
Step 4) After 30 minutes, the animals were placed on the stereotaxic frame (Harvard instru-
ments, Holliston, MA) by putting the ear bars into the ear canals such that the animal is locked 
correctly. This was confirmed as there was no lateral movement of the head.  
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Step 5) The front teeth of the rat was put over the incisor bar and was slided away from the 
animal as far as possible to lock the head. The nose clamp was then tightened. 
Step 6) The shaved part of head was cleaned with iodine and incision was made with a scalpel. 
Using retractors the skull was exposed and to minimize blood from the wound area, epinephrine 
(100µg/mL) was used. 
Step 7) The skull was scraped to remove the adhering tissue so that bregma (reference point for 
stereotaxic surgery of the brain) is easily distinguishable. 
Step 8) The probe holder was adjusted such that its tip exactly points the bregma. The values of 
the three coordinates (dorso-ventral, medio-lateral and anterio-posterior) were recorded by 
reading the vernier scale.  
Step 9) The appropriate coordinates for drilling a hole in the hippocampus region of the rat brain 
were calculated. 
Step 10) Using a dentist’s drill a hole was made carefully in the hippocampus region such that 
the drill goes only through the skull without damaging the blood vessels. 
Step 11) After the hole is drilled, using a small needle the dura mater (the outermost layer of the 
meninges surrounding the brain) was punctured. 
Step 12) Microdialysis probe was fixed on to the probe holder and slowly inserted into the hole 
drilled in the hippocampus region (anterior-posterior = 5.6 mm, medio-lateral = 5 mm, dorso-
ventral = 7 mm, from bregma).  
Step 13) Using a microinjection pump, the microdialysis probes were equilibrated by perfusing 
KRB buffer at a rate of 2 µL/min for a period of one hour. 
Step 14) The animals were given maintenance doses of anesthesia (ketamine 40 mg/kg + 
xylazine 10 mg/kg) intravenously as needed.  
23 
 
Figure 4: Pictorial representation of the stereotaxic frame used for carrying out microdialysis 
in rats. 
Step 15) The microdialysis fractions were collected at hourly intervals for 6 h following 
intranasal administration and the dialysate was assayed by ELISA (see section 5.1.8). 
 
 
 
 
 
 
 
 
 
 
 
The change in the concentration of NGF over time was used to calculate the pharmacokinetic 
parameters using a noncompartmental pharmacokinetic model. The area under the curve was 
calculated by trapezoidal rule. The maximum concentration (Cmax) was directly read from the 
plot.  
 
5.1.8. Assay of GF  
The NGF in the receiver compartments from in vitro experiments and the microdialysates from 
in vivo studies were assayed by ELISA using “NGF Emax ImmunoAssay system”. ELISA is 
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capable of discriminating the intact peptide from its metabolites and reflects only the actual 
content of NGF, unlike in the case of radiolabeled substrates where the label could be associated 
either with intact neurotrophins or its metabolite such that measuring the total label content does 
not reflect the actual concentration of neurotrophins (60, 63).  
Elisa procedure: 
 Step 1) The required number of wells were coated with 100 µL of carbonate coating buffer 
(0.025 M sodium bicarbonate and 0.025 M sodium carbonate, pH 9.7) containing anti-NGF pAb. 
The wells are covered and incubated overnight at 4
0
C so that the antibody adheres to the plastic 
through charge interactions.  
Step 2) The wells were washed once with wash buffer (20 mM Tris-HCl, 150 mM sodium 
chloride, 0.05% (v/v) tween 20) and 200 µL of Block & Sample buffer 1X was added and 
incubated for 1h at room temperature so as to bind the non specific binding sites. 
Step 3) The wells were washed once with wash buffer and NGF standard (100 µL) were added 
to each well of the first column by performing serial dilutions. Samples to be analyzed were 
added to the wells starting from the second column. The wells were incubated with shaking for 6 
h at room temperature.  
Step 4) After 6 h the wells were washed 5 times using the wash buffer and 100 µL of Block & 
Sample buffer 1X containing Anti-NGF mAb was added and incubated overnight without 
shaking at 4
0
C. 
Step 5) The wells were washed 5 times using the wash buffer and 100 µL of Block & Sample 
buffer 1X containing Anti-rat IgG, horseradish peroxidase (HRP) conjugate was added and 
incubated for 2.5 h at room temperature. 
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Step 6) The wells were washed 5 times using the wash buffer and 100 µL of TMB (3, 3’, 5,5”-
tetramethylbenzidine) solution was added to each well and incubated with shaking for 10 
minutes at room temperature. The addition of TMB resulted in production of blue color due to 
the reaction between TMB substrate and HRP conjugate. 
Step 7) After 10 minutes the reaction was stopped by adding 100 µL of 1 N HCl and the samples 
were analyzed using a plate reader at 450 nm. 
The amount of NGF in the samples is proportional to the color generated in the 
oxidation-reduction reaction. The sensitivity of the NGF assay was about 7.8 pg/mL. 
 
5.1.9. Microscopic studies 
The probe implantation site was examined by microscopic examination of coronal brain sections. 
The rats were euthanized via carbon dioxide inhalation. Brains were placed in formalin for 5 
days and then embedded in 8% w/w gelatin. The gel block was hardened and cryoprotected in 
20% w/w sucrose formalin for 2 days before sectioning at 50 µm on a Leica 1800 cryostat. 
Sections were mounted, stained with cresyl violet, and cover slipped with dibutyl phthalate 
xylene (DPX). 
 
5.1.10. Statistical analysis 
Statistical analysis was carried out using Graph Pad Prism 5 software. The unpaired t-test was 
selected as the test of significance and p value less than 0.05 was considered as level of 
significance.  
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Figure 5: Effect of different grades of chitosan [low viscosity (LCH), medium viscosity (MCH) 
and high viscosity (HCH)] at different concentration on in vitro permeation of FD40K across 
bovine olfactory mucosa. The data points provided are an average of six trails with SEM as 
error bars. 
5.2. Results and Discussion 
5.2.1. Screening of different grades of chitosan for potential enhancer 
Chitosan has been shown to render the olfactory mucosa more permeable to macromolecules. 
The mechanism was speculated to be due to opening of tight junctions in the mucosa which 
opens up convective transport channels across the barrier (3, 64, 65).       
Invariably, all the chitosan grades (low viscosity, medium viscosity and high viscosity) at 
three different concentrations (0.1% or 0.25% or 0.5% w/v) used in this study were able to 
enhance the permeation of FD40K across the olfactory mucosa at the end of 2 h (Figure 5). 
However, the extent of enhancement differed between different grades and concentrations. In 
general the enhancement factor decreased at 0.5% w/v chitosan concentration in all the cases 
which is likely due to increased viscosity of the donor solution.  
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Figure 6: Effect of medium viscosity grade chitosan (MCH) at different concentrations on in 
vitro permeation of #GF across bovine olfactory mucosa. The data points provided are an 
average of six trails with SEM as error bars. 
The medium viscosity grade chitosan was more efficient compared to other two grades of 
chitosan as a permeation enhancer. The medium viscosity grade chitosan enhanced the 
permeation of FD40K by ~7 fold, ~11 fold and ~11 fold at 0.1%, 0.25% and 0.5% w/v 
concentration respectively, over control (0.06 ± 0.52 µg/cm2). Therefore, this grade of chitosan 
was used to investigate the effect on permeation of NGF in in vitro studies. 
 
5.2.2.  In vitro permeation studies 
Medium viscosity grade chitosan enhanced the NGF permeation across the bovine olfactory 
mucosa by ~8 fold, ~45 fold and ~37 fold at 0.1%, 0.25% and 0.5% w/v concentration 
respectively, over control (0.10 ± 0.02 ng/cm2) (Figure 6).  
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However, there was no statistically significant (p > 0.05) difference in the permeation of NGF 
when 0.25% and 0.5% w/v chitosan was used. Therefore, 0.25% w/v chitosan was used for all 
our future studies. 
In order to determine the effect of chitosan on permeability status of the olfactory 
mucosa, the electrical resistance was monitored before and after incorporation of chitosan. 
Trans-olfactory epithelial electrical resistance has been reported to reflect the permeability status 
of the epithelial membranes (66). Therefore, the electrical resistance was measured in the current 
studies and the membranes with resistance > 2 kΩ cm
2
 only were used or the in vitro permeation 
studies. In presence of the chitosan the trans-olfactory epithelial electrical resistance dropped 
significantly (p = 0.003) by ~34.50 ± 4.06% after 30 minutes indicating the ability of the 
chitosan to permeabilize the olfactory mucosa. Electrical resistance is considered to be a rather 
qualitative parameter and did not show any quantitative dependence on the concentration of the 
enhancer. The most intriguing observation of the study was the recovery of trans-olfactory 
epithelial electrical resistance following replacement of chitosan with the KBR buffer in the 
donor compartment after the permeation studies. The electrical resistance of the membrane was 
found to recover almost completely within 1-2 h (Figure 7). 
This suggests that chitosan acts as an enhancer by a mechanism which permeabilizes the 
membrane reversibly and not by mechanical disruption of the membrane. Similar observations 
found with chitosan in other biological membranes have been attributed to the opening and 
closing of tight junctions during permeabilization and recovery phases respectively (38, 67). 
Based on these observations, it can be speculated that chitosan could be acting as a drug 
permeation enhancer across the olfactory mucosa by opening the tight junctions. 
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Figure 7: Relative electrically resistivity of the bovine olfactory mucosa during permeation 
studies. After 6 h of permeation study, the #GF solution in the donor compartment was 
replaced with KRB buffer and the electrical resistivity was monitored (recovery phase). The 
data points provided are an average of six trials and error bars represent the standard error of 
mean (SEM). 
 
 
 
 
 
 
 
 
 
5.2.3.  In vivo brain microdialysis 
The drug level in the extracellular fluid is known to determine the drug activity and toxicity in 
any tissue. Microdialysis is a technique which is most commonly used to investigate the release 
of neurotransmitters in the brain (68-72). The technique is capable of sampling the drug from the 
perineural fluid of the brain. Therefore, microdialysis was carried out to investigate the time 
course of free NGF in the perineural fluid. Moreover, CNS disorders such as Alzheimer’s and 
Parkinson’s are caused by degeneration of neurons specifically in the hippocampus region. The 
nose to brain pathway for drugs is well established and has been reported to deliver the NGF 
directly to the hippocampus region of the brain where most of the NGF receptors are situated 
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(62).
 
Therefore, in the present study, the nose to brain delivery of NGF was investigated by 
carrying out brain microdialysis in the hippocampal region.   
 
 
 
 
 
 
 
Figure 8: A representative photomicrograph showing insertion of microdialysis probe into 
hippocampus region of rat brain during brain microdialysis (a) and the probe implantation site 
which included the rat hippocampal region (b).  
 
The recovery of the microdialysis probe was 4.2 ± 0.3%. The basal value of unbound NGF in 
rats was 163.31 ± 3.36 pg/mL.  The basal NGF levels observed in our studies are lower than that 
reported in prior studies. Hoener et al., determined the endogenous level of NGF in rat 
hippocampus as 738 pg/mL (73). The same was reported to be 1336 pg/mL by Fawcett et al (74). 
This could be due to the fact that the previous reports on nose to brain delivery of NGF were 
based on the measurements of NGF in whole tissue homogenates (62, 63). Whereas, in this 
project the reported NGF value represents the free NGF present in the extracellular fluid.  The 
Cmax in rats treated with chitosan and NGF was 1008.62 ± 130.02 pg/mL which was significantly 
higher than that for rats given NGF only 97.38 ± 10.66 pg/mL (p = 0.014). 
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Figure 9: Concentration-time profile of #GF in rat hippocampus following intranasal  
administration. The data points represent baseline adjusted values and are averages of three  
animals with SEM as error bars. 
The brain bioavailability of intranasally administered NGF was enhanced by ~14 fold as 
calculated by ratio of area under the curve up to 6 h in chitosan vs non-chitosan groups (Figure 
9). However, there was no significant difference in the elimination half life of NGF between 
these two groups (Table 1).  
 
 
 
 
 
 
 
 
 
Table 1: Pharmacokinetic parameters of intranasally (I#) administered #GF group and #GF + 
0.25 % w/v chitosan group. 
 
Parameters I GF group 
I (GF + 0.25% w/v 
chitosan) group 
p value 
Cmax (pg/mL) 97.38 ± 10.66 1008.62 ± 130.02 0.014 
AUC (pg h/mL) 209.79 ± 14.06 2692.46 ± 94.74 0.002 
Elimination half life 
(1/h) 
0.45 ± 0.08 0.52 ± 0.05 0.06 
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CHAPTER-6 
    BRAI DERIVED EUROTROPHIC FACTOR  
 
Brain-derived neurotrophic factor (BDNF) is one of the most important neurotrophic factors 
which promote survival of all major neuronal types affected in neurodegenerative disorders and 
also responsible for generation of cholinergic neurons in the basal forebrain and hippocampus 
region (75-77). BDNF is capable of protecting neurons from amyloid peptides which are 
neurotoxic in contrast to other members of neurotrophin family which are less effective in 
rescuing neurons from these neurotoxins (78).  
BDNF and its receptors are abundantly expressed in the central nervous system, 
especially in the hippocampus and basal forebrain region (75, 77-81). This is the region of brain 
in which most of the neurodegeneration is observed in case of Alzheimer’s, Parkinson’s, 
Huntington’s disease, etc. Therefore, it is necessary to delivery BDNF to hippocampus and basal 
forebrain region if one attempts to treat these disorders using BDNF.  
In addition to its neuroprotective effect, BDNF plays a critical role in psychiatric 
disorders like stress and depression (82). Decreased BDNF levels have been reported in various 
animal models subjected to stress (83). In case of depression also, the expression of BDNF is 
decreased. From the outcome of various studies, it has been hypothesized that presence of 
normal level of BDNF in the brain is very important because of its ability to inhibit the cell death 
cascades, modulate the plasticity and to increase the cell survival proteins (84-86). 
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The regulation of BDNF expression by antidepressant drugs has been demonstrated. However, 
the treatment of chronic depression condition using antidepressants is associated with a long 
delayed onset of action and prolonged treatment duration (87, 88). In addition, the systemic side 
effects associated with such prolonged antidepressant drug therapy is considerably high. 
Shirayama et al., demonstrated the antidepressant effect of BDNF by infusing BDNF into 
hippocampus of behavioral models of depression in (learned helplessness and forced swim test) 
(89). There are various strategies employed for direct delivery of BDNF into the brain like direct 
injection or by using minipumps or gene therapy (90, 91). Unfortunately, all these methods lack 
practical clinical relevance and would result in significant systemic side effect (48). Bruke et al., 
observed that intracerebroventricular injection of BDNF resulted in relatively poor diffusion of 
BDNF into the brain parenchyma. Moreover, BDNF when delivered systemically via parenteral 
route is not bioavailable to the brain due to the metabolism of the peptide or due to the blood 
brain barrier (BBB) and blood cerebrospinal fluid (BCSF) barrier (92). In addition, the 
hydrophilic and macromolecular nature (~28kDa dimeric protein of non-covalently linked 14 
kDa subunits) of the therapeutic agent limits its permeation across biological barriers (93). 
Therefore, there is need for an alternative safe, non invasive route of delivery which bypasses the 
BBB and delivers the drug to the affected regions of the brain over sustained time periods.  
 
6.1. Materials and Methods 
6.1.1. Chemicals 
BDNF Emax ImmunoAssay system and rhBDNF were purchased from Promega Corporation, 
Madison, WI. Freshly excised bovine olfactory mucosa was purchased from Pel-Freez  
Biologicals (Rogers, AR). 
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6.1.2. Preparation of chitosan and BDF solution 
The chitosan solution was prepared by dissolving the required quantity of chitosan in a fraction 
of 1% glacial acetic acid solution prepared in KRB buffer (pH 5.5). The second fraction of the 
KRB buffer was used to dissolve the BDNF. The BDNF and chitosan solutions were mixed by 
vortexing. The solutions prepared without incorporation of chitosan served as control. 
 
6.1.3.  In vitro permeation studies 
In vitro experimental set up procedure is same as described in section 5.1.3. The donor 
compartment was filled with 100 µL of BDNF solution (50 µg/mL prepared in KRB buffer) with 
medium viscosity grade chitosan of different concentrations (0.1% or 0.25% or 0.5% w/v) and 
the receiver compartment with 5 mL KRB buffer. Control set of experiments were run without 
incorporation of chitosan in the donor solution. The amount of BDNF permeated across the 
bovine olfactory mucosa was determined by assaying the samples collected from the receiver 
compartment at the end of 2 h by ELISA using “BDNF Emax ImmunoAssay system” (see section 
6.1.6).  
 
6.1.4.  Stability of BDF in the tissue homogenate 
Freshly procured bovine olfactory mucosa of same weight was taken in a glass vial and 
homogenized in KRB buffer. To this known concentration of BDNF was spiked and incubated at 
37
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C for 12 h. Before the start of experiment, zero time point sample was taken to know the 
initial activity of BDNF. Samples were withdrawn at regular intervals of time, diluted 
accordingly and quantified by ELISA. 
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6.1.5.  In vivo brain microdialysis 
The in vitro calibration of microdialysis probes (CMA 12, CMA Microdialysis, Sweden) was 
carried out by the method described by Vaka and Co-workers (94). Brain microdialysis was 
carried out in male, Sprague dawley rats (250–300 g, Harlan Company, Indianapolis, IN, U.S.A) 
under ketamine (80 mg/kg) and xylazine (10 mg/kg) anesthesia (i.p. injection). The experimental 
procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Mississippi (Protocol # 10–017). The rats were divided into 4 groups (n=3). The 
first 3 groups of rats were laid on their back after anesthetizing and formulations were 
administered intranasally using a microsyringe connected with a soft polymer capillary directly 
into the posterior segment of the nose. Chitosan solution (0.25% w/v prepared in KRB buffer 
was administered intranasally (vehicle control group) to group 1. BDNF solution prepared in 
KRB (100 µL of 50 µg/mL) without incorporation of chitosan was administered intranasally to 
 
group 2, whereas, BDNF solution (100 µL of 50 µg/mL) with 0.25% w/v chitosan prepared in 
KRB was intranasally administered to 
 
group 3. To rats belonging to group 4, BDNF solution 
(100 µL of 50 µg/mL) with 0.25% w/v chitosan prepared in KRB was administered via i.v route.    
After administration of formulations to different groups the rats were secured on a 
stereotaxic frame (Harvard Instruments, Holliston, MA) and brain microdialysis was carried out 
by inserting the probe into the hippocampal region (anterior-posterior=5.6 mm, medio-lateral=5 
mm, dorso-ventral=7 mm, from bregma) (94). The microdialysis probes (CMA 12) were 
equilibrated by perfusing KRB at the rate of 2 µL/min using a microinjection pump for a period 
of 1h. The rats were given maintenance doses of anesthesia [ketamine (40 mg/kg) and xylazine 
(10 mg/kg)] after 3 h from the start of the study. The microdialysis samples were collected at 
hourly intervals for 6 h and quantified by ELISA. The pharmacokinetic parameters were 
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calculated using a noncompartmental pharmacokinetic model. The area under the curve was 
calculated by trapezoidal rule.  
 
6.1.6.  Assay of BDF 
The BDNF in the receiver compartments from in vitro experiments and the microdialysates from 
in vivo studies were assayed by ELISA using “BDNF Emax ImmunoAssay system” 
Elisa procedure: 
 Step 1) The required number of wells were coated with 100 µL of carbonate coating buffer 
(0.025 M sodium bicarbonate and 0.025 M sodium carbonate, pH 9.7) containing anti-BDNF 
mAb. The wells are covered and incubated overnight at 4
0
C so that the antibody adheres to the 
plastic through charge interactions.  
Step 2) The wells were washed once with wash buffer (20mM Tris-HCl, 150mM sodium 
chloride, 0.05% (v/v) tween 20) and 200 µL of Block & Sample buffer 1X was added and 
incubated for 1h at room temperature so as to bind the non specific binding sites. 
Step 3) The wells were washed once with wash buffer and BDNF standard (100 µL) were added 
to each well of the first column by performing serial dilutions. Samples to be analyzed were 
added to the wells starting from the second column. The wells were incubated with shaking for 2 
h at room temperature.  
Step 4) After 2 h the wells were washed 5 times using the wash buffer and 100 µL of Block & 
Sample buffer 1X containing Anti-human BDNF  pAb was added and incubated with shaking for 
2 h at room temperature. 
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Step 5) The wells were washed 5 times using the wash buffer and 100 µL of Block & Sample 
buffer 1X containing Anti-IgY, horseradish peroxidase (HRP) conjugate was added and 
incubated with shaking for 1 h at room temperature. 
Step 6) The wells were washed 5 times using the wash buffer and 100 µL of TMB (3, 3’, 5,5”-
tetramethylbenzidine) solution was added to each well and incubated with shaking for 10 
minutes at room temperature. The addition of TMB resulted in production of blue color due to 
the reaction between TMB substrate and HRP conjugate. 
Step 7) After 10 minutes the reaction was stopped by adding 100 µL of 1 N HCl and the samples 
were analyzed using a plate reader at 450 nm. 
The amount of NGF in the samples is proportional to the color generated in the oxidation-
reduction reaction. The sensitivity of the BDNF assay was about 7.8 pg/mL. 
 
6.1.7.  Pharmacodynamic studies 
These studies were approved by the institutional animal ethical committee (Protocol # 
VCP/IAEC/AB23-2010). The rats were divided into 5 groups (n=6). The first four groups of rats 
were subjected to immobilization stress before carrying out the forced swim test by taping the 
four limbs of rats to a wooden board with two metal loops around the neck for 2 h a day for 
seven consecutive days. The formulations were administered 2 h prior to study on 8
th 
day as 
described in section 6.1.5 by anesthetizing the rats using isoflurane (5%). One more vehicle 
control group of rats which were not subjected to immobilization stress (Group 5) was included 
in these studies in order to determine the immobility time in the absence of stress. After the rats 
were completely recovered from anesthesia they were placed individually in a glass container 
with water at a depth of 30 cm (23–25°C) for 10 minutes. (89, 95). The immobility time of five 
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groups of rats was recorded. Fresh water was used each time and the experiments were 
performed during the same time of the day. The rats which were floating and making only the 
necessary movements to keep its nostrils above the water surface were considered immobile.  
 
6.2. Results and Discussion 
6.2.1. Chitosan enhanced the in vitro permeation of BDF  
Medium viscosity grade chitosan was found to enhance the BDNF permeation across the bovine 
olfactory mucosa by ~7 fold, ~14 fold and ~5 fold at 0.1%, 0.25 % and 0.5% w/v concentration 
respectively, over control (18.78 ± 16.69 ng/cm2) (Figure 10). The mechanism of permeation 
enhancement could be due to a combination of several mechanisms. Vaka et al., reported earlier 
that chitosan lead to a significant drop in the electrical resistivity of the mucosa indicating the 
possible interaction of the polymer with the mucosal membrane (94).  
The electrical resistivity was also found to recover with time suggesting that the 
permeabilization of the membrane by the chitosan is reversible. It is likely that the drop in 
electrical resistivity is due to opening of the tight junctions present in the membrane. However, 
the role of ionic charge interaction between the polymer and BDNF, hydrokinetic transport and 
other possible mechanisms cannot be overruled. Further, 0.25% w/v medium viscosity grade 
chitosan was used to study its permeation enhancement efficiency in vivo. 
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Figure 10: Effect of medium viscosity grade chitosan (MCH) at different concentrations on 
in vitro permeation of BD#F across bovine olfactory mucosa. The data points provided are 
an average of six trails with SEM as error bars. 
 
 
 
 
 
 
 
 
 
6.2.2.   Stability of BDF in the tissue homogenate 
Olfactory mucosa has a milieu of enzymes in it (15). The enzymes serve a protective function to 
prevent accidental entry of toxins via nose to brain pathway. BDNF being a peptide in nature is 
very amenable to enzymatic degradation. It has been reported that there are several proteolytic 
enzymes on the nasal mucosa surface, which could result in degradation of peptide and protein 
drugs (36-38). Therefore, the stability of BDNF in the homogenate of the mucosal tissue was 
investigated as it contains both inter and intracellular enzymes. The BDNF degradation followed 
an apparent first order kinetics. The degradation rate constant calculated from the semi 
logarithmic plot of percentage BDNF remaining as a function of time was found to be 0.39 ± 
0.05 h
-1
. These studies indicate that the poor transport of BDNF across the olfactory mucosa is 
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also likely due to significant degradation of BDNF in the membrane in addition to poor 
membrane permeability.  
 
6.2.3. In vivo brain microdialysis 
In general, the total BDNF (bound and unbound) levels in the whole brain homogenates are 
estimated (34, 87). However, the free or unbound levels of BDNF in the perineural fluid of rat 
hippocampus are known to determine the drug activity and toxicity. Hence, microdialysis 
technique was used in order to estimate the free BDNF levels. The recovery of microdialysis 
probes was 2.98 ± 0.2 %. The BDNF levels in group one served as average baseline endogenous 
levels (206.91 ± 56.94 ng/L). The time course of exogenous BDNF in the brain (the difference 
between the total amount of BDNF and baseline endogenous level) was plotted and the 
bioavailability parameters were calculated. The brain bioavailability of group 3 rats was 
significantly enhanced by ~13 fold compared to group 2 (Figure 11). This increased 
bioavailability could be attributed to chitosan which acts as a barrier modulating agent by 
transient permeabilization of the olfactory mucosa.  
In addition, some amount of BDNF may be transported by receptor mediated endocytosis 
due to the presence of the physiologic receptor for BDNF (trkB) on mature olfactory neurons and 
by intracellular transport (96). There was no significant enhancement of BDNF levels in case of 
group 4 compared to group one (vehicle control). The Cmax achieved in group 3 rats at 2 h was 
685.63 ± 94.37 ng/L which was significantly higher than the Cmax achieved (50.62 ± 35.85 ng/L) 
in group 2 rats at 4 h.  
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Figure 11: Concentration - time profile of BD#F in rat hippocampus following intranasal /i.v 
administration of different formulations. The data points represent baseline adjusted values and 
are averages of three animals with SEM as error bars. 
 
 
 
 
 
 
 
 
However, the concentrations achieved in rat hippocampus upon intranasal administration at 60 
min in our studies were less than that reported by Alcala-Barraza et al (1700 ± 600 ng/L) upon 
intranasal administration of [
125
I]-BDNF (70 µg) (34). This difference in concentrations is due to 
the fact that the authors have estimated the total amount of BDNF (bound and unbound) in tissue 
homogenates. Kafitz et al., demonstrated that BDNF at a low nanomolar range excited neurons 
in the hippocampus and cortex as rapidly (less than 10 ms) as the classic excitatory 
neurotransmitter glutamate (97).   
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6.2.4.  Pharmacodynamic Studies 
The forced swim test is one of the most commonly used paradigms to assess the effect of stress 
on immobility time in rodent models (89, 98, 99). In this test the rats subjected to acute stress are 
forced to swim in a restricted space from which they cannot escape. When rats are previously 
subjected to stress leading to depression, the immobility time is increased (83, 89). 
 The immobility time of group 5 rats, which were not subjected to immobilization stress is ~ 
2 fold less than that of group 1 rats (Figure 12). Smith and coworkers have shown that repeated 
immobilization of rats reduces BDNF levels in the rat brain, especially in the hippocampus (83). 
Intranasal administration of formulation containing BDNF solution (100 µL of 50 µg/mL) with 
0.25% w/v chitosan prepared in KRB to group 3 significantly decreased the immobility time 
compared to that of group 1 (vehicle control group). These results clearly indicate the potential 
of nose to brain delivery of BDNF formulations containing chitosan in replenishing the depleted 
BDNF levels. Siuciak et al., and Shirayama et al., studied the effect of infusion of BDNF into the 
rat brain on the immobility time and reported such similar observations (89, 100). The 
antidepressant effect of BDNF is believed to be the result of interference of hippocampal 
synaptic transmissions by BDNF with stress (89, 101-103) . In case of rats belonging to groups 2
 
and 4 the immobility time was not significant  statistically (p > 0.05) compared to that of group 1 
(vehicle control group). This is likely due to the poor brain bioavailability of BDNF as seen in 
pharmacokinetics studies.  
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Figure 12: The effect of BD#F on duration of immobility in the forced swim test upon 
intranasal/i.v administration of formulations. The data points represent baseline adjusted 
values and are averages of six animals with SEM as error bars (***p<0.001). 
 
 
 
 
 
 
 
 
 
 
These studies showed that significant amounts of BDNF could be delivered to brain via nose to 
brain pathway with the aid of barrier modulating agent like chitosan. Continuous stress in rats 
leads to depression like condition, likely due to depletion of BDNF. Repletion of BDNF using 
intranasal formulations can counteract the stress induced depression. Therefore, it appears that 
intranasal delivery of BDNF with chitosan could potentially treat CNS disorders associated with 
BDNF depletion. 
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CHAPTER-7 
     CAROSIC ACID 
 
Carnosic acid (MW ~330 daltons), a phenolic diterpene isolated from rosemary (Rosmarinus 
officinalis) leaves extract has been reported to promote the synthesis of NGF in the human 
glioblastoma cells and enhance BDNF production in dopaminergic neuronal cell lines (104-106). 
In addition, the carnosic acid is already known for its neuroprotective effect, antioxidant, anti-
inflammatory, antibacterial, anticancer and antiplatelet activity (106-111).  
 
 
 
 
 
 
 
 
7.1. Materials and Methods 
7.1.1. Chemicals 
Carnosic acid, Krebs ringer bicarbonate (KRB) buffer (premixed powder) and chitosan were 
procured from Sigma chemicals (St. Louis, MO, USA). Acetonitrile and phosphoric acid were 
Figure 13: Structure of carnosic acid 
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purchased from Fisher Scientific (Pittsburgh, PA, USA). Hydroxy propyl-beta-cyclodextrin (HP-
β-CD) was procured from Roquette Pharma (Keokuk, IA, USA). All solutions were prepared in 
deionized water. Brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF) Emax 
ImmunoAssay systems were procured from Promega Corporation (Madison, WI). The bovine 
olfactory mucosa was purchased from Pel-Freez Biologicals (Rogers, AR).  
 
7.1.2. Analytical method 
The amount of carnosic acid permeated across bovine olfactory mucosa (in vitro) was quantified 
by measuring the samples collected from the receiver compartment using high performance 
liquid chromatography (HPLC) system (Waters, 1525) with an autosampler (Waters, 717 plus) 
consisting of a Phenomenex C18 (2) 100 R analytical column (4.6 mm X 150 mm, Luna, 5.0 
mm) and a dual λ absorbance detector (Waters, 2487). Mobile phase consisted of acetonitrile and 
0.1 % phosphoric acid solution (55:45, v/v) (111). Elution was performed isocratically at 25
0
C at 
a flow rate of 1.5 mL/min. Injection volume was 100 µL and the column effluent was monitored 
at 210 nm. The range for the calibration curve was 50-1000 ng/mL (R
2
=0.99). 
 
7.1.3. Phase solubility studies of carnosic acid 
The phase solubility study was carried out to determine the stoichiometry according to the 
method reported by Higuchi and Connors (112). An excess amount of carnosic acid was added to 
solution of HP-β-CD prepared in KRB buffer at various concentrations (0.002—0.143 M). The 
contents were stirred for 24 h at room temperature. After equilibrium the samples were filtered 
and analyzed by HPLC. 
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7.1.4. In vitro permeation studies 
In vitro experimental set up procedure is same as described in section 5.1.3. 
The donor and receiver compartments were filled with carnosic acid solution (500 µL of 
1mg/mL) and 5 mL of KRB buffer + 20% HP-β-CD, respectively. The effect of different 
concentrations of medium viscosity grade chitosan (0.1% or 0.25% or 0.5% w/v) on the 
permeation of carnosic acid across bovine olfactory mucosa was studied. Control set of 
experiments were run without incorporation of chitosan in the donor solution. Samples were 
collected at 1 h intervals for 6 h and analyzed by HPLC. 
 
7.1.5. In vivo brain microdialysis 
In vitro calibration of microdialysis probes (CMA 12, CMA Microdialysis, Sweden) was carried 
out according to the method reported by Vaka et al. (94). In vivo studies were carried out in 
male, Sprague dawley rats (250-300 g, Harlan Company, Indianapolis, IN) under anesthesia 
[ketamine (80 mg/kg) + xylazine (10 mg/kg); i.p injection]. The experimental procedures were 
approved by the Institutional Animal Care and Use Committee (IACUC) at the University of 
Mississippi (Protocol # 10-017). The rats were divided into 5 groups (n=3). To the first four 
groups of rats, formulations were administered by intranasal (i.n) route whereas, to the fifth 
group of rats formulation was administered by subcutaneous (s.c) route as stated below: 
To group 1 rats, 0.25% w/v chitosan in HP-β-CD solution (vehicle control group) (i.n 
route); group 2- carnosic acid (4 mg/kg) in HP-β-CD solution (i.n route); group 3-carnosic acid 
(2 mg/kg): HP-β-CD solution with 0.25% w/v chitosan (i.n route); group 4-carnosic acid (4 
mg/kg): HP-β-CD solution with 0.25% w/v chitosan (i.n route); group 5-carnosic acid: HP-β-CD 
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solution with 0.25% w/v chitosan by s.c route (dose equivalent to that administered by i.n route 
to group 4).  
After four days of administration of different formulations to 5 groups of rats via 
intranasal/s.c route, the brain microdialysis was carried out by securing the rats in the stereotaxic 
frame (Harvard Instruments, Holliston, MA) and inserting the probe (CMA 12) into the 
hippocampal region (anterior-posterior=5.6 mm, medio-lateral=5 mm, dorso-ventral=7 mm, 
from bregma) (94). Intranasal formulations were administered to the rats by placing them on 
their back after giving mild anesthesia and inserting a micro syringe connected with a soft 
polymer capillary directly into posterior segment of the nose. The microdialysis probes were 
equilibrated by perfusing KRB buffer at the rate of 2 µL/min using a microinjection pump for a 
period of 1h. The microdialysis samples were collected after four days of administration 
(intranasal/s.c route) of formulations and assayed for NGF (see section 5.1.8) and BDNF (see 
section 6.1.6) by ELISA.  
 
7.2. Results and Discussion 
7.2.1. Phase solubility studies of carnosic acid  
The inherent aqueous solubility of carnosic acid was 25 ng/mL, whereas the solubility in case of 
KRB buffer was 3 µg/mL. Phase solubility studies revealed that the carnosic acid solubility was 
enhanced significantly with increase in concentration of HP-β-CD (Figure 14). The solubility of 
carnosic acid was enhanced to 2.7 mg/mL at 20% HP-β-CD. However, the stoichiometry does 
not appear to reflect a covalent or insertion complexation between HP-β-CD and carnosic acid. 
Loftsson et al., demonstrated that the drug/cyclodextrin complexes can self associate to form 
water soluble aggregates/microaggregates of several drug/cyclodextrin complex units which 
eventually solubilize water insoluble lipophilic drugs through non-inclusion complexation (113, 
114). 
Carnosic acid to HP-~-CD ratio was 1:18 suggesting the formation of aggregates or a 
micellar structures leading to enhanced solubility of camosic acid. Nevertheless, the solubility of 
camosic acid was enhanced by ~900 fold at 20% cOl1centration of HP-~-CD over its inherent 
solubility in KRB buffer. Hence, it was decided to use 1: 18 ratio of camosic acid: HP-~-CD in 
further studies. 
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Figure 14: Phase solubility diagram of carnosic acid at different concentrations of 
hydroxypropyl fJ cyclodextrin (HP-fJ-CD). The data points provided are average offour trails 
and error bars represent SEM 
7.2.2. In vitro permeation studies of carnosic acid across bovine olfactory mucosa 
Chitosan enhanced the permeation of camosic acid across the bovine olfactory mucosa by ~3 fold, 
~8 fold and f"'W7 fold at 0.1 %, 0.25% and 0.5% w/v concentrations, respectively over control (17.20 
± 6.67 J.lg/cm2) (Figure 15). Recently, chitosan was reported to lead to a significant drop in the 
50
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Figure 15: Effect of different concentrations of chitosan (CH) on in vitro permeation of 
carnosic acid across the bovine olfactory mucosa. The data points provided are average of four 
trails and error bars represent SEM. 
 
electrical resistivity of the mucosa indicating the interaction of the polymer with the mucosal 
membrane.  
Moreover, the electrical resistivity was also found to recover with time suggesting that 
the permeabilization of the membrane by the chitosan is reversible. It is likely that the drop in 
electrical resistivity is due to opening of the tight junctions present in the membrane (94). Such 
similar observations were found using chitosan in other biological membranes (38, 67). As the 
amount of carnosic acid permeated with the use of 0.25 % w/v chitosan was not significant 
statistically (p > 0.05) compared to that of 0.5% w/v chitosan, 0.25% w/v chitosan was used to 
develop intranasal formulation for in vivo studies. 
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7.2.3. Delivery of carnosic acid - In vivo 
Carnosic acid was reported to promote the synthesis of NGF and BDNF in the human 
glioblastoma and dopaminergic neuronal cell lines, respectively (104, 105). It has been reported 
that the catechol portion of the carnosic acid play an important role in stimulating NGF synthesis 
(104, 115). However, the exact mechanism of BDNF elevation by carnosic acid is still unclear. 
In most of the neurodegenerative disorders, the degeneration is localized in the 
hippocampus region of the brain. Therefore, it would be appropriate to monitor the levels of 
neurotrophins in this region. Microdialysis is a minimally invasive technique of sampling 
therapeutic agents from the tissue fluids. The method allows sampling of drug from specific 
regions of the brain (68-72). Hence, microdialysis technique was employed in this study to 
sample the free neurotrophin (NGF and BDNF) levels in the hippocampus region of rat brain.      
The recovery of microdialysis probes in case of NGF studies was 4.2 ± 0.3%, whereas, 
the recovery was found to be 2.98 ± 0.2% in studies involving BDNF. The endogenous NGF and 
BDNF levels in the vehicle control group (group 1) were found to be 124.01 ± 28.06 ng/L and 
206.91 ± 50.94 ng/L, respectively. The enhancement in the BDNF levels was about 50% in case 
of group 2, which was significantly higher (p < 0.05) than the control group. On the other hand, 
there was no significant enhancement in the NGF levels in group 2 over group 1. This suggests 
that the threshold or effective concentration of carnosic acid to upregulate expression of 
significantly high levels of NGF is relatively higher than that of BDNF, which was obviously not 
attained with intranasal administration of only carnosic acid.  In case of intranasal administration 
of carnosic acid solution (2 mg/kg) with chitosan (group 3), the NGF and BDNF levels in the rat 
hippocampus region were enhanced by ~3 and ~2 fold over group 1, respectively (Figures: 16 a 
53 
 
& b). It is most likely that the chitosan in the formulations enhanced the bioavailability of 
carnosic acid, thus leading to a better biological response. 
In order to study the effect of escalation of dose of carnosic acid on the upregulation of 
BDNF and NGF, 4 mg/kg dose of carnosic acid solution with chitosan was administered via 
intranasal route to group 4. Interestingly, there was no enhancement in the NGF levels but the 
BDNF levels were enhanced by ~ 1.5 fold when compared to group 3 in which 2 mg/kg carnosic 
acid solution with chitosan was administered via intranasal route (Figures: 16 a & b). These 
findings were not in accordance with that reported by Kosaka and Yokoi, where they have 
observed an increase in NGF synthesis (~25 fold) in the human gliobastoma cell lines by 
carnosic acid in concentration dependent manner (5-100 µM) (104). 
 Additional mechanistic studies need to be carried out to explain the difference in dose 
dependence response between in vitro and in vivo models. Till date there are no reports regarding 
the mechanism of absorption of carnosic acid across mucosal membranes and the nature of dose 
dependent pharmacokinetics of carnosic acid. Hence, further studies on these lines would explain 
the differences observed between in vitro and in vivo results.  
 The systemic bioavailability of drugs is generally high following subcutaneous 
administration as compared to non-parenteral routes. However, the bioavailability of drugs into 
the brain may vary depending on physicochemical properties of drugs and the absorption 
mechanism across the blood brain barrier. In this study, the levels of carnosic acid in the brain 
could not be quantified. This was because the microdialysis recovery of carnosic acid was poor 
due to high lipophilicity and poor water solubility. However, when carnosic acid solution (4 
mg/kg) was administered via s.c route (group 5) there was again only a 50% increase in the 
BDNF and NGF levels in the brain (Figures: 16 a & b). This suggests that the parenteral 
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Figure 16: Concentration of (a) nerve growth factor (#GF) and (b) brain derived neurotrophic 
factor (BD#F) in rat hippocampus after four days of administration of carnosic acid 
formulations by intranasal/s.c route. The data points represent average values of three animals 
with SEM as error bars. 
administration would also deliver effective levels of carnosic acid into brain. However, frequent 
administration and invasiveness limits the parenteral administration in patients.  
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CHAPTER-8 
     FORMULATIO OF CAROSIC ACID AOPARTICLES 
 
Nasal mucociliary clearance is one of the most important limitation for intranasal drug delivery 
as it severely limits the residence time of drugs in the nasal cavity thereby effectively ruling out 
the possibility of sustained nasal drug administration (116). Nanoparticulate drug delivery 
systems have been reported to improve significantly the bioavailability of drugs upon intranasal 
administration as compared to drug solutions (117-121). These formulations were shown to 
increase the residence time in the nasal cavity and also protect the drugs from the enzymatic 
degradation (121). Fernandez-Urrusuno et al., reported that upon intranasal administration of 
chitosan nanoparticles loaded with insulin to rabbits, the plasma glucose levels was lowered to 
60% of the original value. Whereas, the chitosan-insulin solution was found to lower the plasma 
glucose levels to only 85% of the original value. The reason for this was stated to be due to the 
intensified contact of the nanoparticles to the epithelium (118). In another study, it was reported 
that cationic Biovector
TM 
nanoparticle system formulated using polysaccharides, dipalmitoyl 
phosphatidyl choline and cholesterol had an extended mean residence half life of 2.3 h in the 
human nasal cavity when compared to that of the residence half life (15-30 minutes) of solution 
form  (122, 123). 
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On the basis of our previous study, our objective was to prepare carnosic acid nanoparticles 
aiming to maintain prolonged therapeutic levels by increasing the residence time and thereby 
reducing the frequency of administration.  
 
8.1.  Materials and Methods 
8.1.1. Chemicals 
Carnosic acid, chitosan, tripolyphosphate (TPP), glacial acetic acid were procured from Sigma 
chemicals (St. Louis, MO, USA). Hydroxy propyl-beta-cyclodextrin (HP-β-CD) was procured 
from Roquette Pharma (Keokuk, IA, USA). All other reagents and solvents used were of 
analytical grade. 
 
8.1.2. Formulation of nanoparticles 
Experimental Design:  
Central Composite Design (CCD) is a well suited response surface methodology (RSM) 
employed for fitting a quadratic surface. This design is one of the commonly used RSM designs 
employed for process optimization. CCD is used to establish the design space and optimize the 
process parameters with lesser number of runs compared to other RSM designs. RSM 
methodology is used in the present context to produce nanoparticles with optimum 
physicochemical properties that are expected to produce the most desirable efficacy in vivo.   
 Face Centered Design (FCD) is a type of CCD which provides relatively high quality 
predictions over the entire design space and do not require using points outside the original 
factor range. Moreover, it has good design properties like little co-linearity, insensitive to outliers 
and missing points. A 20-run, 3
3
 Face centered design consisting of 3 factors at 3 levels was set 
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up using Design-Expert
®
 8.0.2 Demo version software to produce the carnosic acid loaded 
nanoparticles. The effect of three critical factors namely chitosan concentration, TPP 
concentration and sonication time on the responses like particle size, zeta potential, drug 
encapsulation efficiency and drug release were systematically investigated. The factors and the 
corresponding levels as per the design have been represented in Table 2.     
  
 
 
 
 
 
 
 
Carnosic acid loaded chitosan nanoparticles were prepared by ionic interaction. Different 
concentrations of chitosan (4 mL of 0.1 or 0.55 or 1% w/v) were prepared to which carnosic acid 
was added. Then, 1 mL of TPP solution (0.1 or 0.55 or 1 % w/v) was added. The solution was 
ultrasonicated using a very high intensity microprobe with a diameter of 3.2 mm and a 100 W 
high intensity processor (Microson XL-2000, VWR International, West Chester, PA, USA). The 
probe was immersed into the solution and ultrasonication was carried out for 2 or 6 or 10 
minutes and the nanoparticles were characterized immediately. 
 
 
 
Figure 17:  Face Centered Design (FCD) depicting factorial () and axial points (O). 
8.1.3. Characterization of nanoparticles 
The particle size and zeta potential of different batches of nanoparticles were determined by 
Zetasizer Nano- ZS (Malvem Instruments Inc., Westborough, MA, USA). The particle size was 
measured based on photon correlation spectroscopy (PCS or dynamic light scattering, DLS) 
technique, which is a powerful tool for estimatil1g the particle size of fine particles ranging from 
a few nanometers to micrometers (124). The zeta potential was determined based on 
electrophoretic light scattering technique. 
8.1.4. Determination of encapsulation efficiency 
The encapsulation efficiency of different formulations was determined by separation of 
nanoparticles from the aqueous suspension containing non-entrapped camosic acid by taking 200 
f.lL of formulation in 0.5 mL centrifugal filter units and centrifuging at 5000 rpm for 7 minutes. 
The solution collected in the tube after centrifugation was diluted accordingly and analyzed by 
HPLC to determine the amount of free canlosic acid (see section 7.1.2). The encapsulation 
efficiency (% EE) was calculated according to the equation below: 
Total amount of camosic acid- Free amount of camosic acid 
%EE X 100 
Total anlount of camosic acid 
8.1.5. In vitro release study 
Carnosic acid release from chitosan nanoparticles was determined by taking 1mL of the 
formulation in a dialysis bag clamped at both ends. The dialysis bag was then placed in a beaker 
containing 100 ml of20% HP-~-CD solution with slow magnetic stirring at room temperature. 
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Samples (10 mL) were withdrawn at regular intervals of time up to 12 h and replaced with same 
volume to maintain sink conditions. The collected samples were diluted accordingly and 
quantified by HPLC (see section 7.1.2). 
 
8.1.6.  In vitro mucoadhesion studies 
These studies were carried out using bovine olfactory mucosa. A known amount of nanoparticles 
(100 mg) was sprinkled on to the mucosa which was mounted on a glass slide. Then the glass 
slide was placed in desiccator for about 15 minutes so as to allow the polymer to interact with the 
membrane. After 15 minutes, the glass slide was taken out from the desiccator and was placed at 
an angle of 45
0
. The KRB buffer was circulated over the mucosa at the rate of 100 µL/min and 
the washings were collected and freeze dried. The weight of the washed out nanoparticles was 
determined and the percent mucoadhesion was calculated as follows (125). 
                                          % mucoadhesion = (Wi - Wf ) X 100/ Wi 
Where, Wi is the weight of the nanoparticles applied to the mucosa and Wf  represents the weight 
of the nanoparticles washed out. 
 
8.1.7.  Atomic force microscopy (AFM) studies 
The morphology and particle size measurements of the nanoparticles were performed by AFM 
(Picoscan
TM 
2500, Molecular imaging corporation). The sample was prepared by depositing 
nanoparticle solution on freshly cleaved mica surface and dried by nitrogen gas. Images were 
acquired in non-contact mode using silicon nitrite cantilever with frequency of 150 KHz. 
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8.1.8.  In vivo studies 
In vivo studies were carried out in male, Sprague dawley rats (250-300 g, Harlan Company, 
Indianapolis, IN) under anesthesia [ketamine (80 mg/kg) + xylazine (10 mg/kg); i.p injection]. 
The experimental procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Mississippi (Protocol # 10-017). The rats were divided 
into 3 groups (n=3) each for (a) solution (administered only once), (b) solution (administered 
daily once for four days) and (c) nanoparticulate formulation (administered only once). 
To group 1 rats - 0.25% w/v chitosan (vehicle control group), to group 2 - carnosic acid 
(4 mg/kg) with 0.25% w/v chitosan was administered by intranasal route and to group 3 - 
carnosic acid with 0.25% w/v chitosan was administered by s.c route (dose equivalent to that 
administered by intranasal route). After four days the rats were anesthetized and brain 
microdialysis was carried out by securing them on the stereotaxic frame (Harvard Instruments, 
Holliston, MA) and inserting the probe (CMA 12) into the hippocampal region. The 
microdialysis samples were collected and assayed for NGF (see section 5.1.8) and BDNF (see 
section 6.1.6) by ELISA.  
 
8.1.9.  Microscopic studies 
In order to determine the toxicity of the formulations, rats treated with intranasal carnosic acid 
formulations were euthanized and the olfactory tissue and brain were collected and fixed for 16 h 
at 4
0
C using freshly made, pre-chilled (4
0
C) phosphate buffered saline (PBS)-4% 
paraformaldehyde. The tissues were then washed in PBS for 20 minutes for 3 times at room 
temperature, transferred into 65% ethanol (30 minutes), and finally transferred to 70% ethanol 
for storage. Tissues were then trimmed and embedded in paraffin, sectioned and stained with 
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hematoxylin and eosin for routine histological examination. Tissue sections were evaluated 
histologically using an Olympus BX41 light microscope (Olympus America, Inc., Center Valley, 
PA), and images were captured with an Olympus digital camera (model DP20) using appropriate 
software supplied by the manufacturer. 
 
8.1.10.  Optimization 
In order to test the potential of the carnosic acid nanoparticles, an attempt to optimize the 
formulations was made by determining how various factors influence the physicochemical 
properties of the nanoparticles. The effect of  three critical factors namely chitosan 
concentration, TPP concentration and sonication time on the responses  such as particle size, zeta 
potential, drug encapsulation efficiency and drug release were systematically investigated (Table 
2). The particle size is a key parameter that is assumed to dictate the in vivo absorption and drug 
release kinetics whereas the zeta potential was known to determine the physical stability of the 
formulation. 
 
8.1.11.  Regression analysis 
The response parameters were statistically analyzed by applying one-way ANOVA at 0.05 level 
using Design-Expert
®
 8.0.2 Demo version software. The individual parameters were evaluated 
using the F test and Quadratic models as shown in equation were generated for each response 
using multiple regression analysis (MLRA).  
Y = β0 + β1 X1 + β2 X2 + β3 X3 + β11 X1
2 
+ β22 X2
2 
+ β33 X3
2 
 + β12 X1X2 + β23 X2X3 + β13 X1X3 + 
+ β14 X1 X2X3 
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Where Y is the level of the measured response, β0  is the intercept,  β1 - β14 =  regression 
coefficients, X1 , X2 , X3 = Factors, X1 X2 , X2 X3 , X1 X3 represent the two-way Interaction terms 
while X1X2X3 stands for three-way interaction. 
8.1. Results and Discussion 
0"\ 
w 
Formulation TPP (0A.) 
Chitosan 
(0h.) 
Time 
(minutes) 
Particle size 
(nm) 
Zeta 
potential (mV) 0A. EE 
0/0 Release 
(12 h) 
1 0.55 0.55 6 475.24 ± 12.15 27.10 ± 3.21 72.18 ± 3.26 29.44 ± 3.18 
2 1 1 2 374.67 ± 10.86 18.20± 1.80 40.98 ± 4.72 19.53 ± 1.07 
3 1 0.1 10 182.34 ± 15.40 20.30 ± 2.03 74.57 ± 2.48 32.76 ± 2.60 
4 0.55 0.55 6 410.45 ± 33.67 28.50 ± 1.20 75.36 ± 3.31 34.3 ± 2.81 
5 0.1 1 10 747.31 ± 59.82 26.10 ± 1.16 51.18 ± 6.20 23.58± 1.55 
6 0.1 0.1 2 310.12 ± 28.21 34.30 ± 2.43 74.93 ± 2.17 40.74 ± 1.76 
7 0.1 0.1 10 212.36 ± 21.02 38.60 ± 2.8 83.68 ± 2.08 52.52 ± 2.08 
8 0.55 0.55 6 495.21 ± 40.20 25.90 ± 2.03 68.22 ± 1.52 29.79 ± 2.61 
9 1 1 10 785.64 ± 68.31 20.20 ± 1.65 47.28 ± 1.97 18.66 ± 2.29 
10 1 0.1 2 250.27 ± 29.53 23.60 ± 1.09 64.57 ± 1.03 29.33 ± 1.57 
11 0.55 0.55 6 436.21 ± 36.77 27.80± 1.55 78.61 ± 2.95 37.42 ± 2.51 
12 0.1 1 2 831.25 ± 20.94 24 ± 0.82 57.32 ± 1.51 19.50± 1.68 
13 0.55 0.1 6 345.27 ± 37.30 30.90 ± 2.61 86.94 ± 2.03 50.46 ± 3.64 
14 0.1 0.55 6 625.72 ± 42.88 34.10 ± 2.17 76.57 ± 1.76 38.07 ± 3(;07 
15 1 0.55 6 400.26 ± 39.14 16.40 ± 2.30 62.32 ± 1.33 28.37 ± 2.33 
16 0.55 0.55 10 354.12 ± 13.56 34.60 ± 0.91 80.19 ± 1.90 34.89 ± 2.57 
17 0.55 1 6 612.45 ± 60.28 27.10 ± 2.63 51.63 ± 2.83 17.01 ± 2.96 
18 0.55 0.55 6 471.69 ± 18.20 30.60 ± 2.45 77.06 ± 2.11 48.32 ± 2.05 
19 0.55 0.55 6 510.87 ± 31.13 31.90 ± 2.82 72.32 ± 1.48 34.6 ± 1.68 
20 0.55 0.55 2 568.64 ± 40.32 26.70 ± 1.90 68.32± 1.06 28.94 ± 1.32 
Table 2: The composition of20 formulations and the results obtainedfor particle size, zeta potential, % encapsulation efficiency and % release. 
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 Summary of AOVA as per Design Expert version 8.0.2:  
8.2.1. Particle size 
Mathematical model is linear  
TPP has a negative influence on the particle size while chitosan is found to have a positive 
influence on the particle size as depicted by the mathematical model. 
 
 
‘Values of "Prob > F" less than 0.05 indicate model terms are significant, two factors were found 
to be significant: TPP and chitosan concentration,  
Extent of significance: Chitosan > TPP, (the F value suggest that chitosan has greater impact on 
particle size than TPP)  
Equation in terms of actual factors: Particle size = 308.99 – 163.02 X TPP + 455.77 X 
chitosan 
Contour plot: Portrayed a linear trend, the particle size was found to incease with decrease in  
the TPP concentration while it was found to increase with increase in chitosan concentration.  
The target particle size of 250 nm could be achieved using low concentration of chitosan (< 0.2% 
w/v).  
The plots are color coded, with blue representing the low values and red representing the high 
values. The values increase as the color changes from blue to green to yellow to red. 
 
Source d.f Sum Square Mean Square F-value Prob > F Significance 
Model 2 474500 237200 25.24 < 0.0001 Significant 
TPP 1 53814 53814 5.73 0.0285 Significant 
Chitosan 1 420600 420600 44.76 < 0.0001 Significant 
Lack of fit 12 152800 12735 9.15 0.0119 Significant 
Table 3:  A#OVA for the particle size 
Particle size (nm) 
\.00 ---...,......,,--=-----=~--__<_--_=----~____:"'" 
0.90 
Figure 18: Contour plot showing the effect ofchitosan and TPP conc on the particle size. 
3-D plot: Particle size decreased linearly with decrease in the chitosan concentration while 
fractionally declined with increase in TPP concentration. 
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Figure 19: 3-D plot showing the effect ofTPP and chitosan concentration on the particle size. 
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8.2.2. Zeta potential 
Mathematical model is linear 
TPP and chitosan have a negative influence on the zeta potential 
Source d.f Sum Square Mean Square F-value Prob > F Significance 
Model 2 444.1 222.05 18.13 < 0.0001 Significant 
TPP 1 341.06 341.06 27.84 < 0.0001 Significant 
Chitosan 1 103.04 103.04 8.41 0.01 Significant 
Lack of fit* 12 183.16 15.26 3.04 0.1138 Not Significant 
Table 4: ANOVAfor the zeta potential 
Values of "Prob > F" less than 0.05 indicate model terms are significant, two factors were found 
to be significant: TPP and Chitosan concentration, Extent of significance: TPP > chitosan (The 
F value indicates that TPP has greater impact on zeta potential compared to chitosan) 
Equation in terms of actual factors: Zeta potential = 38.41 - 12.98 X TPP conc - 7.13 X 
chitosan concentration. 
Contour plot: Portrayed a linear trend, The zeta potential deceased with increase in the TPP and 
chitosan concentrations. 
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Figure 20: Contour plot showing the effect of chitosan and TPP cone on the zeta potential. 
66
 
The target zeta potential of 30 mV could be only achieved at TPP concentrations between 0.1 to
 
0.6% w/v and chitosan concentrations between 0.1-1 % w/v.
 
3-D plot: Shows a linear decrease in zeta potential with increase in the TPP concentration while
 
the change in zeta potential with increase in chitosan concentration was mot clearly distinct.
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Figure 21: 3-D plot showing the effect of chitosan and TPP cone on the zeta potential. 
8.2.3. Encapsulation efficiency 
Mathematical model is quadratic 
Source d.f Sum Square Mean Square F-value Prob > F Significance 
Model 5 2841.13 568.23 34.65 < 0.0001 Significant 
TPP 1 291.27 291.27 17.76 0.0009 Significant 
Chitosan 1 1857.96 1857.56 113.29 < 0.0001 Significant 
Sonication 
time 1 94.68 94.68 5.77 0.0307 Significant 
TPP2 1 116.33 116.33 7.09 0.0185 Significant 
Chitosan2 1 122.59 122.59 7.48 0.0161 Significant 
Lack of fit* 9 157.57 17.51 1.22 0.4366 Not Significant 
Table 5: ANOVAfor the encapsulation efficiency 
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Values of "Prob > F" less than 0.05 indicate model terms are significant, two factors were found 
to be significant, TPP and chitosan concentration.
 
Extent of significance: The F value indicates that, chitosan > TPP > Sonication time (chitosan
 
has the most pronounced influence on % EE compared to the other two factors)
 
Equation in terms of actual factors: Encapsulation efficiency = 74.7 + 20.75 X TPP conc +
 
3.33 X chitosan conc + 0.76 X sonication time - 29.77 X TPP concz- 30.56 X chitosan concz 
Encapsulation efficiency (Chitosan vs TPP Cone) 
Contour plot: Portrayed a curvilinear trend, the % EE deceased with increase in the chitosan 
and TPP concentrations, the % EE can be maximized using low concentrations of chitosan (0.1 ­
0.2 % w/v) with TPP in the concentration range between 0.2 to 0.5% w/v. 
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Figure 22: Contour plot showing the effect of chitosan and TPP concentration on encapsulation 
efficiency. 
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3-D plot: displays a curvilinear decline in % EE with increase in the chitosan concentration. But, 
the influence of TPP on the % EE is not clearly demonstrated by the 3-D plots. 
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Figure 23: 3-D plot showing the effect of chitosan and TPP concentration on encapsulation 
efficiency. 
Encapsulation efficiency (TPP conc vs Sonication time) 
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Figure 24: Contour plot showing the effect of TPP concentration and sonication time on 
encapsulation efficiency. 
69 
Contour plot: Shows a curvilinear trend at low TPP concentration and later tends to become 
linear at high TPP concentration. The % EE can be maximized at high sonication time with TPP
 
in the concentration range between 0.25 to 0.45%.
 
3-D plot: displays a curvilinear decline in % EE with increase in the TPP concentration.
 
However, the positive influence of TPP concentation on % EE seem to be less evident.
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Figure 25: 3-D plot showing the effect of TPP concentration and sonication time on 
encapsulation efficiency. 
Encapsulation efficiency (Chitosan conc vs Sonication time)
 
Contour plot: Show a curvilinear trend at low chitosan concentration and linear trend at high
 
chitosan concentration. The % EE can be maximized using low concentration of chitisan (0.1 ­
0.2% w/v).
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Figure 26: Contour plot showing the effect of chitosan concentration and sonication time on 
encapsulation efficiency. 
3-D plot: displays a curvilinear decrease in % EE with increase in chitosan concentration. The 
influence of sonication time on the % EE is not clearly obvious in the plots below 
90 
80 
70 
60 
50 
40 
10.00 1.00 
0.90 
800 O~ 
6~0 050060070 
040 
Sonication time (min.) 4 00 ~030 Chltosan concentration (%) 
2.00 0.10 
Figure 27: 3-D plot showing the effect of chitosan concentration and sonication time on 
encapsulation efficiency. 
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8.2.4. % Release @ 12h 
Mathematical model generated was found to be linear 
Source d.f Sum Square Mean Square F-value Prob > F Significance 
Model 2 1356.97 678.49 17.72 < 0.0001 Significant 
TPP 1 200.7 200.7 5.24 0.0351 Significant 
Chitosan 1 1156.27 1156.27 30.20 < 0.0001 Significant 
Lack of fit* 12 411.45 34.29 0.72 0.7069 Not Significant 
Table 6: ANOVAfor the % release @ 12 h
 
Values of "Prob > F" less than 0.05 indicate model terms are significant, two factors were found
 
to be significant: TPP and chitosan concentration.
 
Extent of significance: The F value signifies that chitosan > TPP (chitosan concentration was found
 
to have a greater influence on the release @ 12 h compared to TPP concentration)
 
Equation in terms of actual factors: % Drug release @ 12 h =51.07 - 9.95 X TPP concentration
 
(%) - 23.89 X chitosan concentration (%)
 
% Release @ 12h (Chitosan vs TPP cone): Contour plot is found to be linear.
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Figure 28: Contour plot showing the effect of chitosan and TPP conc on % release @ 12 h 
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Chitosan and TPP concentrations were found to exert a negative influence on the release @ 12 h.
 
The target release (50% @ 12 h) would be plausible at low concentrations of chitosan and TPP
 
(0.1-0.2% w/v)
 
3-D plot: The drug release is shown to decrease linearly with increase in the concentration of
 
chitosan. The influence of TPP on the drug release seems to be less evident in the plots.
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Figure 29: 3-D plot showing the effect of chitosan and TPP cone on % release @12 h 
Chitosan nanoparticles are generally formulated by chemical cross-linking with different kinds 
of polyanions (glycyrrhetic acid, polyaspartic acid, etc.) and other oppositely charged molecules 
yielding controlled drug release formulations with less toxicity (126, 127). However, the most 
extensively used polyanion is tripolyphosphate. Chitosan - TPP nanoparticles were formed by 
means of electrostatic interaction between the positively charged amino groups of chitosan and 
negatively charged phosphate and hydroxide groups of TPP aqueous solution, which compete 
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type of interaction were reported to have strong adhesion and immediate immobilisation on to 
negatively charged mucosal surfaces (129). 
 The particle size was found to increase with increase in chitosan concentration while it 
was found to increase with decrease in the TPP concentrations. The geater influence of the 
chitosan on the particle size compared to the TPP concentration is clearly obvious from the 3-D 
plot (Figure 19). The increase in particle size could be attributed to the increase in viscosity of 
the polymer solution due to increase in polymer concentration. The target particle size of 250 nm 
could be achieved using low concentrations of chitosan (< 0.2% w/v). The zeta potential plays an 
important role in the interactions with mucin glycoproteins, (that is the olfactory mucosa) as well 
as it influences physical stability. The zeta potential was found to decrease with increase in the 
TPP concentration while it was marginally decreased with increase in chitosan concentrations. 
The target zeta potential of 30  mV could be only achieved at TPP concentrations between 0.1 to 
0.6% w/v. The plots indicate that % EE decreased with increase in the chitosan and TPP 
concentrations, therefore, the %  EE can be maximized using low concentrations of chitosan with 
TPP in the concentration range between 0.2 to 0.5% w/v. In addition, the % EE can be 
maximized at high sonication time. Chitosan and TPP were found to exert a negative influence 
on the release @ 12 h. The plots portray that the target release (50% @ 12 h) would be plausible 
at low concentrations of chitosan and TPP (0.1-0.2% w/v). The drug release was shown to 
decrease linearly with increase in the concentration of chitosan. However, the influence of TPP 
on the drug release was seen to be less evident from the plots. 
 The mathematical models generated were validated by preparing further three new 
formulations which differed totally in composition and processing time from the model 
formulations employing desirability approach. Constraints were set on each of the responses 
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(particle size ~250 nm, zeta potential ~30 mV, maximum encapsulation efficiency and ~50% 
release in 12 h) to establish the composition of the new formulations (Table 7). The new 
formulations developed were evaluated and the experimental values of the responses were 
compared with those predicted by the mathematical models. The comparison of the two sets of 
values along with the prediction error involved is shown in Table 8. 
Formulation 
No 
TPP 
cone (%) 
Chitosan 
cone (%) 
Sonication 
time (Min) 
Particle 
size (nm) 
Zeta 
Potential 
(mV) 
% Encap 
effeciency 
% Drug 
Release @ 
12 h Desirability 
21 0.80 0.10 7.25 224.20 27.31 77.87 40.72 0.823 
22 0.55 0.10 10.00 264.65 30.53 84.82 43.19 0.818 
23 0.65 0.10 5.65 248.73 29.26 80.01 42.22 0.812 
Table 7: The results ofthe optimizedformulations obtainedfor particle size, zeta potential, % encapsulation 
efficiency and % release. 
~ 
Table 8: Comparison ofexperimentally observed responses ofthe optimizedformulations with that ofthe 
predicted responses. 
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Figure 30: Contour plot offormulation 23, showing the value ofdesirability at 
different concentrations of chitosan and TPP. 
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Figure 31: 3-D plot offormulation 23, showing the value ofdesirability at 
different concentrations of chitosan and TPP. 
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The prediction error for the response parameters of formulation 23 was found to be range from 
 -4.19 to 14.48 that was much lesser when compared to that of formulations 21 & 22. The low 
values of the prediction error proved the validity of the mathematical models generated by 
ANOVA and multi linear regression analysis (MLRA). Considering the low prediction error, the 
formulation 23 was used to carry out in vitro mucoadhesion, AFM, in vivo and microscopic 
studies. 
The in vitro mucoadhesion studies carried out across bovine olfactory mucosa indicated 
that the percent mucoadhesion of the nanoparticles decreased from 86% to 73% over a period of 
6 h. AFM studies revealed the size of the nanoparticles to be ~250 nm.  
Upon intranasal administration of 0.25% w/v chitosan solution (vehicle control group) to 
group 1 rats the endogenous NGF and BDNF levels were found to be 124.01 ± 28.06 ng/L and 
206.91 ± 50.94 ng/L, respectively. Whereas, upon intranasal administration of 4 mg/kg carnosic 
acid solution with chitosan (0.25% w/v) to group 2 rats the NGF levels were enhanced by ~3.2 
fold and the BDNF levels by ~2.7 fold as compared to control group. However, when carnosic 
acid solution (4 mg/kg) was administered via subcutaneous route (group 3) there was ~50% 
increase in the BDNF and NGF levels in the brain compared to control group. Interestingly, 
when these formulations were administered in the form of nanoparticles only once in contrary to 
that of solution which was administered daily once for a period of 4 days there was no 
statistically significant difference in the NGF and BDNF levels between the 3 groups of rats 
(Figure 32). However, when the formulations were administered in the form of solution only 
once, the NGF and BDNF levels even after 4 days were not statistically significant from the 
vehicle control group. These results clearly indicate that carnosic acid nanoparticles could reduce 
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Figure 32: Concentration of #GF and BD#F in the rat hippocampus after administration of  
carnosic acid formulations [solution administered daily once for 4 days and nanoparticles (#Ps) 
administered only once]. 
Figure 33: Representative pictures of rat olfactory tissue belonging to (a) untreated group 
(b) treated with intranasal formulation of carnosic acid and chitosan. 
 
the frequency of administration and also could maintain prolonged therapeutic levels due to 
higher retention time at the site of delivery. 
Microscopic studies of hematoxylin and eosin stained olfactory and brain sections from treated 
and control animals was performed.  
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Figure 34: Histology of the dentate gyrus of the hippocampus (20 X magnifications, 
bar=500µm) A. Untreated (control) B. Carnosic acid (4mg/kg) treated C. Carnosic acid 
(4mg/kg) and chitosan (0.25% w/v) treated. Histologically normal neurons and glial cells of the 
dentate gyrus of the hippocampus (400X magnification, bar=20µm) D. Untreated (control). E. 
Carnosic acid (4mg/kg) treated F. Carnosic acid (4mg/kg) and chitosan (0.25% w/v) treated. 
In all animals the brain was architecturally normal. Additionally, no cytopathologic 
abnormalities i.e., apoptosis/necrosis of neurons or glial cells, inflammatory infiltrates, or glial 
scars were found. The tissues are architecturally and histologically normal. These studies 
demonstrate that the intranasal administration of formulations containing carnosic acid and/or 
chitosan has no adverse affects even upon frequent administration. 
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The novel findings of this study indicates that the nose-brain delivery of small molecular size 
therapeutic agents like carnosic acid along with chitosan as barrier modulating agent in the form 
of nanoparticles will have a significant positive impact on the treatment of broad-spectrum 
neurodegenerative and CNS disorders. The brain bioavailability following parenteral 
administration appears to be poor. Therefore, the intranasal delivery strategy would circumvent 
the limitations associated with parenteral delivery.  
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CHAPTER-9 
     DELIVERY OF ATIBIOTICS 
 
Meningitis is an infection of the cerebrospinal fluid and meninges that surround the brain and 
spinal cord. Bacterial meningitis is primarily caused by three main bacterial species (Neisseria 
meningitidis, Streptococus pneumonia, Haemophilus influenza type B) and it accounts to three 
fourth of the meningitis infected world population. Bacterial meningitis is more common in 
African, American and Asian countries. Generally, it is treated using large doses of antibiotics 
such as chloramphenicol and cephalosporins (72, 130, 131). Effective levels of antibiotics should 
be maintained in the brain all through the treatment period for successful treatment of meningitis. 
In most of the developing countries, despite their greater potency, the use of cephalosporins is 
limited due to their high cost.   
Cefotaxime is one of the cephalosporins recommended for the treatment of bacterial 
meningitis and is generally administered via parenteral or oral route (132-134). The systemic 
delivery of cephalosporins including cefotaxime is associated with the potential risk of causing 
severe systemic side effects (135-137). Moreover, the drug has short elimination half-life in the 
brain, hence frequent administration is inevitable during the treatment. Therefore, there is need 
for a patient compliant method to deliver cefotaxime to the brain. 
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9.1. Materials and Methods 
9.1.1. Chemicals 
Cefotaxime sodium salt, chitosan (MW ~250 kDa, 75-80% deacetylation), Krebs-ringer 
bicarbonate (KRB) buffer (premixed powder), 1-butanol, potassium phosphate (monobasic) were 
procured from Sigma chemicals (St.Louis, MO, USA).Chloroform, phosphoric acid and 
acetonitrile were obtained from Fischer Scientific (Atlanta, GA,USA). 
 
9.1.2. In vitro permeation studies 
In vitro experimental set up procedure is same as described in section 5.1.3. 
The effect of different concentrations of chitosan (0.1% w/v and 0.25% w/v) on the 
permeation of cefotaxime was investigated by taking 500 µL of drug solution with chitosan in 
the donor compartment. The receiver compartment was filled with KRB buffer (5 mL). Drug-
chitosan solution was prepared by dissolving the required quantity of chitosan in 1% glacial 
acetic acid solution in KRB buffer followed by addition of cefotaxime (1 mg/mL). Control set of 
experiments were run without incorporation of chitosan in donor solution. The amount of 
cefotaxime permeated across the olfactory mucosa was determined by analyzing the samples 
collected from the receiver compartment by HPLC.  
 
9.1.3. Analytical method 
The HPLC system (Waters, 1525) consisting of a Phenomenex C-18 analytical column (4.6 mm 
X 150mm, Luna 5.0µ) and a variable wavelength detector (Waters, 2487) was used. The mobile 
phase was made up of 0.007M phosphoric acid in water-acetonitrile (85:15 v/v). The flow rate 
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was 1.3 mL/min and the column effluent was monitored at 254 nm. The range of calibration 
curve was 0.025 µg/mL to 1 µg/mL (R
2 
= 0.99) (138). 
 
9.1.4. Extraction of cefotaxime  
The plasma obtained from untreated rats was spiked with known concentrations of cefotaxime 
and calibration curve was plotted using the analytical method. 
The rat plasma samples containing cefotaxime were extracted initially by vortexing 1mL 
of plasma with 0.4 M HCl. Then 7 mL of chloroform-1-pentanol (3:1) was added to the mixture 
and vortexed for 30 minutes followed by centrifugation for a period of 10 minutes at 1000 g. 
From this organic phase (5 mL) was collected and 350 µL of phosphate buffer (pH 7) was added 
to it so as to back extract (30 minutes) the cefotaxime which was then centrifuged for a period of 
10 min. The upper aqueous phase was quantified by HPLC (139).  
 
9.1.5. In vivo brain microdialysis  
Pharmacokinetic studies were carried out in Sprague Dawley rats (male, 250-300 g; Harlan 
Company, Indianapolis, IN, USA). The experimental procedures were approved by the 
Institutional animal care and use committee (IACUC) at the University of Mississippi (Protocol 
# 10-017). The rats were categorized into four groups (n=3 for groups 1 & 2 and n=6 for groups 
3 & 4). The rats were anesthetized using ketamine (80 mg/kg) and xylazine (10 mg/kg) (i.p 
injection).  
Cefotaxime solution with 0.25% w/v chitosan (40 mg/kg) was administered by i.v route 
to rats in groups 1 & 3 and intranasally (i.e. administration of drug directly into the posterior 
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segment of the nose using a microsyringe connected with a soft polymer capillary) to groups 2 & 
4.  
In case of rats belonging to groups (1 & 2), the time course of drug in the brain was 
investigated by performing microdialysis. The microdialysis probe (CMA 12) was inserted into 
brain (anterior-posterior=5.6 mm, medio-lateral=5 mm, dorso-ventral=7 mm, from bregma) after 
securing the rat on a stereotaxic frame (Harvard Instruments, Holliston, MA, USA). The 
microdialysis probes were equilibrated by perfusing KRB buffer at 2 µL/min for a period of 30 
minutes with the aid of a microinjection pump. Following i.v or intranasal administration of 
cefotaxime solution (10 mg in 100 µL) the microdialysis fractions were collected at 15, 30, 60, 
90, 120, 180, 240, 300 and 360 minutes and quantified using HPLC. 
In case of groups 3 and 4 blood samples were collected at 15, 30, 60, 90, 120, 180, 240, 
300 and 360 minutes from retro-orbital plexus using heparinized capillary tubes. Plasma was 
collected from blood samples by centrifuging at 1500 rpm for 15 minutes and cefotaxime was 
analyzed using HPLC after extraction with a hydrochloric acid, chloroform-1-pentanol (3:1) and 
phosphate buffer solvent system.  
 
9.1.6. Pharmacokinetic data analysis 
The area under curve (AUC) was calculated using trapezoidal rule, Cmax and tmax were directly 
obtained from the concentration-time graphs.  
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9.2. Results and Discussion 
9.2.1. In vitro permeation studies 
Chitosan (0.25% w/v) enhanced the permeation of cefotaxime across bovine olfactory mucosa  
by ~1.5 fold and ~2 fold at the end of 1
st
 h and 2
nd
 h respectively, over control (29.56 ± 6.18 
µg/cm
2
). Whereas, there was no significant enhancement in permeation of cefotaxime at 0.1% 
w/v concentration of chitosan (Figure 35). Overall, the enhancement in the permeability of drug 
by chitosan was not as dramatic as that observed in case of NGF (94).  
 
 
 
 
 
 
 
 
 
 
Figure 35: Effect of chitosan (0.1 % or 0.25% w/v) on in vitro permeation of cefotaxime across 
the bovine olfactory mucosa. The data points provided are average of four trails and error bars 
represent SEM. 
 
Therefore, a solution of drug in 0.25% w/v chitosan was used for intranasal and intravenous 
administration in further studies. Further, higher concentrations were not considered due to 
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increased viscosity of the formulation, which might cause discomfort upon intranasal 
administration in rats.  
 
9.2.2. Pharmacokinetics of cefotaxime in the brain  
The in vitro recovery of microdialysis probes was found to be 12.84 ± 1.42%. The recovery of 
cefotaxime from plasma was 39.60 ± 3.25%.   
The Cmax of cefotaxime in the brain following intranasal administration (1.477 ± 0.19 
µg/mL) was found to be less than that observed upon i.v administration (3.286 ± 1.17 µg/mL).  
This difference in Cmax is likely because of drug loss due to absorption of a greater fraction of 
drug from nasal mucosa into the systemic circulation followed by elimination via normal 
clearance. Such similar kind of observations using tetramethylpyrazine was reported earlier by 
Hussian and co-workers as well as Illum (3, 140).  Moreover, the bioavailability (AUC0-∞) of 
cefotaxime in the brain following intranasal administration (0.38 ± 0.06 X 10
3 
min.µg/mL) was 
not significantly different from the bioavailability (AUC0-∞) following i.v administration (0.45 ± 
0.06 X 10
3 
min.µg/mL) (Figure 36). 
However, the time required to achieve maximum concentration (tmax) was less upon 
intranasal administration (30 minutes) compared to i.v administration (180 minutes). Similar 
observations have been reported in case of tetramethylpyrazine. Feng et al, suggest that rapid 
absorption of drug via olfactory region could be due to convective transport of drugs.  This 
ability of drugs to pass through multiple pathways from nose to brain when administered 
intranasally was previously reported (3). 
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Figure 36: Concentration- time profile of cefotaxime in rat hippocampus following intranasal 
/i.v administration. The data points represent baseline adjusted values and are averages of three 
animals with SEM as error bars. 
The minimum concentration at which the drug has the ability to inhibit the bacterial growth is 
defined as Minimum Inhibitory Concentration (MIC). The MIC levels of cefotaxime against 
most bacteria causing meningitis range from 0.01 µg/mL to 0.6 µg/mL (135). From figure 36 it 
is evident that the drug delivered intranasally attained MIC levels rapidly and remained high over 
the MIC through 6 h which is comparable to i.v administration.  
 
 
 
 
 
 
 
 
Provided this data is translatable to humans, it appears that effective levels of drug could be 
achieved in the brain quite rapidly via intranasal administration of drug and frequent 
administration would keep the drug levels fairly consistent through the treatment duration. 
Although the brain levels of cefotaxime are higher following i.v administration (Figure 36), 
intranasal route may be preferred over i.v route because of noninvasiveness and potentially 
minimal side effects. Moreover, overshooting the MIC levels in the brain,  as seen in case of i.v 
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route is not likely to improve the treatment but rather could cause toxicity in case of certain 
drugs with small therapeutic window.  
The bioavailability of drug in the brain following i.v administration was expected to be 
higher than intranasal administration. However, the overall brain uptake following i.v 
administration was found to be comparable to that of intranasal. This could be attributed to the 
rapid hepatic metabolism of drug in the systemic circulation. The major metabolic organ for 
cefotaxime was found to be liver (141, 142). Earlier Tsai et al., reported a Cmax of ~1.9 µg/mL in 
the brain following intravenous administration which is ~2 fold less compared to the present 
case. However, the bioavailability (AUC0-t) did not differ significantly between these two 
studies.   
 
9.2.3. Pharmacokinetics of cefotaxime in plasma 
The drug levels in plasma following intranasal administration were almost an order of magnitude 
less when compared to that of i.v administration (Figure 37). The AUC0-∞ levels following 
intranasal administration and i.v administration were 15.32 ± 3.42 X 10
3 
min.µg/mL and 371.30 
± 191.02 X 10
3 
min.µg/mL, respectively. This data suggests that the drug is likely to undergo 
metabolism in the mucosal membrane. However, low systemic bioavailability following 
intranasal administration is likely to result in less systemic side effects compared to parenteral 
administration.  
The absolute bioavailability of cefotaxime following intranasal administration was 0.041 
± 0.009.  This data suggests that the systemic side effects are likely to be less when cefotaxime is 
administered by intranasal route as compared to intravenous administration.  
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Figure 37: Concentration-time profile of cefotaxime in rat plasma following intranasal /i.v 
administration. The data points represent baseline adjusted values and are averages of three 
animals with SEM as error bars. 
 
 
 
 
 
 
 
 
 
 
Cefotaxime was found to undergo enzymatic metabolism in the liver to   desacetylcefotaxime 
(141, 142). It was also reported that desacetylcefotaxime has only 12% antibacterial activity 
compared to cefotaxime (143). From figure 37 it is evident that the amount of drug that enters 
into the plasma when administered intranasally is less compared to i.v and hence, will metabolize 
to a less extent than administered and retains its antibacterial activity. Apart from retaining its 
activity the unwanted systemic side effects may be minimized. 
It was reported that distribution of cefotaxime following i.v administration was 
instantaneous and extensive in body resulting in rapid equilibration between most body fluids 
and tissues (142, 144). As the amount of drug in plasma when administered intranasally is less 
than i.v (Figure 37), distribution of drug to body fluids and tissues may be comparatively less 
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which may be an additional factor to minimize the unwanted effects of drug in body fluids and 
tissues following intranasal administration. 
These results indicate that intranasal delivery of antibiotics such as cefotaxime would be 
a potential treatment approach for bacterial meningitis. In addition, Nose to brain delivery of 
cefotaxime is non-invasive, allows frequent administration and would minimize the side effects 
associated with systemic delivery. 
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Conclusions 
Considerable anatomical differences between human and rats with respect to olfactory mucosa 
and the brain may influence how the current results translate into human applications. In rats, the 
nasal olfactory mucus covers approximately 50 % of the total nasal epithelium as opposed to 5% 
in humans. The cerebrospinal fluid volume (~160 mL in humans vs 0.25 mL in rats) is replaced 
every 1.5 h in rats compared to every 5 h in humans. The brain interstitial fluid volume is ~260 
mL in humans versus 0.3 mL in rats. Therefore, the drug levels achieved in rats by intranasal 
administration may be an overestimation of what could actually be achieved in humans. 
However, these facts reinforce the necessity of drug bioavailability enhancers like chitosan for 
achieving clinically efficacious levels of drug in the human brain via the nasal pathway given the 
small mucosal area.   
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